
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Janus kinase inhibitors in palmoplantar pustulosis: a mixed-methods feasibility (JAKPPPOT) trial protocol - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="AE5331AC8AF268630531AC0010C2AE90.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="bmjo">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374624/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="BMJ Open">
<meta name="citation_title" content="Janus kinase inhibitors in palmoplantar pustulosis: a mixed-methods feasibility (JAKPPPOT) trial protocol">
<meta name="citation_author" content="David Gleeson">
<meta name="citation_author_institution" content="St. John&#x27;s Institute of Dermatology, Guy&#x27;s &amp; St. Thomas&#x27; NHS Foundation Trust and King’s College London, London, UK">
<meta name="citation_author" content="Sarah Chapman">
<meta name="citation_author_institution" content="Centre for Adherence Research and Education, King’s College London, London, UK">
<meta name="citation_author" content="Helen McAteer">
<meta name="citation_author_institution" content="Psoriasis Association, Northampton, Northamptonshire, UK">
<meta name="citation_author" content="April Qin">
<meta name="citation_author_institution" content="St. John&#x27;s Institute of Dermatology, Guy&#x27;s &amp; St. Thomas&#x27; NHS Foundation Trust and King’s College London, London, UK">
<meta name="citation_author" content="John Gregory">
<meta name="citation_author_institution" content="St. John&#x27;s Institute of Dermatology, Guy&#x27;s &amp; St. Thomas&#x27; NHS Foundation Trust and King’s College London, London, UK">
<meta name="citation_author" content="Jade Pizzato">
<meta name="citation_author_institution" content="St. John&#x27;s Institute of Dermatology, Guy&#x27;s &amp; St. Thomas&#x27; NHS Foundation Trust and King’s College London, London, UK">
<meta name="citation_author" content="Kingsley Powell">
<meta name="citation_author_institution" content="St. John&#x27;s Institute of Dermatology, Guy&#x27;s &amp; St. Thomas&#x27; NHS Foundation Trust and King’s College London, London, UK">
<meta name="citation_author" content="Manpreet K Sagoo">
<meta name="citation_author_institution" content="St. John&#x27;s Institute of Dermatology, Guy&#x27;s &amp; St. Thomas&#x27; NHS Foundation Trust and King’s College London, London, UK">
<meta name="citation_author" content="Weiyu Ye">
<meta name="citation_author_institution" content="St. John&#x27;s Institute of Dermatology, Guy&#x27;s &amp; St. Thomas&#x27; NHS Foundation Trust and King’s College London, London, UK">
<meta name="citation_author" content="Ann Naylor">
<meta name="citation_author_institution" content="Patient and Public Involvement Advisory Group, JAKPPPOT Trial, King’s College London, London, UK">
<meta name="citation_author" content="Lucy Moorhead">
<meta name="citation_author_institution" content="St. John&#x27;s Institute of Dermatology, Guy&#x27;s &amp; St. Thomas&#x27; NHS Foundation Trust and King’s College London, London, UK">
<meta name="citation_author" content="Andrew E Pink">
<meta name="citation_author_institution" content="St. John&#x27;s Institute of Dermatology, Guy&#x27;s &amp; St. Thomas&#x27; NHS Foundation Trust and King’s College London, London, UK">
<meta name="citation_author" content="Richard Woolf">
<meta name="citation_author_institution" content="St. John&#x27;s Institute of Dermatology, Guy&#x27;s &amp; St. Thomas&#x27; NHS Foundation Trust and King’s College London, London, UK">
<meta name="citation_author" content="Jonathan Barker">
<meta name="citation_author_institution" content="St. John&#x27;s Institute of Dermatology, Guy&#x27;s &amp; St. Thomas&#x27; NHS Foundation Trust and King’s College London, London, UK">
<meta name="citation_author" content="James B Galloway">
<meta name="citation_author_institution" content="Centre for Rheumatic Disease, Kings College London, London, UK">
<meta name="citation_author" content="Suzie Cro">
<meta name="citation_author_institution" content="Clinical Trial Statistics, Imperial College London Faculty of Medicine, London, UK">
<meta name="citation_author" content="Satveer K Mahil">
<meta name="citation_author_institution" content="St. John&#x27;s Institute of Dermatology, Guy&#x27;s &amp; St. Thomas&#x27; NHS Foundation Trust and King’s College London, London, UK">
<meta name="citation_author" content="C H Smith">
<meta name="citation_author_institution" content="St. John&#x27;s Institute of Dermatology, Guy&#x27;s &amp; St. Thomas&#x27; NHS Foundation Trust and King’s College London, London, UK">
<meta name="citation_publication_date" content="2025 Aug 21">
<meta name="citation_volume" content="15">
<meta name="citation_issue" content="8">
<meta name="citation_firstpage" content="e106361">
<meta name="citation_doi" content="10.1136/bmjopen-2025-106361">
<meta name="citation_pmid" content="40840981">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374624/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374624/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374624/pdf/bmjopen-15-8.pdf">
<meta name="description" content="Palmoplantar pustulosis (PPP) is a rare, debilitating inflammatory skin disease involving painful pustules on the palms and soles. Janus kinase (JAK) inhibitors target pathways relevant to PPP disease biology but also confer a risk of major adverse ...">
<meta name="og:title" content="Janus kinase inhibitors in palmoplantar pustulosis: a mixed-methods feasibility (JAKPPPOT) trial protocol">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Palmoplantar pustulosis (PPP) is a rare, debilitating inflammatory skin disease involving painful pustules on the palms and soles. Janus kinase (JAK) inhibitors target pathways relevant to PPP disease biology but also confer a risk of major adverse ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374624/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12374624">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1136/bmjopen-2025-106361"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/bmjopen-15-8.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374624%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12374624/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12374624/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374624/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-bmjopen.png" alt="BMJ Open logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to BMJ Open" title="Link to BMJ Open" shape="default" href="http://bmjopen.bmj.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">BMJ Open</button></div>. 2025 Aug 21;15(8):e106361. doi: <a href="https://doi.org/10.1136/bmjopen-2025-106361" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1136/bmjopen-2025-106361</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22BMJ%20Open%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22BMJ%20Open%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22BMJ%20Open%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22BMJ%20Open%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Janus kinase inhibitors in palmoplantar pustulosis: a mixed-methods feasibility (JAKPPPOT) trial protocol</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gleeson%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">David Gleeson</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">David Gleeson</span></h3>
<div class="p">
<sup>1</sup>St. John's Institute of Dermatology, Guy's &amp; St. Thomas' NHS Foundation Trust and King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gleeson%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">David Gleeson</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chapman%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Sarah Chapman</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Sarah Chapman</span></h3>
<div class="p">
<sup>2</sup>Centre for Adherence Research and Education, King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chapman%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sarah Chapman</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22McAteer%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Helen McAteer</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Helen McAteer</span></h3>
<div class="p">
<sup>3</sup>Psoriasis Association, Northampton, Northamptonshire, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22McAteer%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Helen McAteer</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Qin%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">April Qin</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">April Qin</span></h3>
<div class="p">
<sup>1</sup>St. John's Institute of Dermatology, Guy's &amp; St. Thomas' NHS Foundation Trust and King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Qin%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">April Qin</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gregory%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">John Gregory</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">John Gregory</span></h3>
<div class="p">
<sup>1</sup>St. John's Institute of Dermatology, Guy's &amp; St. Thomas' NHS Foundation Trust and King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Gregory%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">John Gregory</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pizzato%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Jade Pizzato</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Jade Pizzato</span></h3>
<div class="p">
<sup>1</sup>St. John's Institute of Dermatology, Guy's &amp; St. Thomas' NHS Foundation Trust and King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pizzato%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jade Pizzato</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Powell%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Kingsley Powell</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Kingsley Powell</span></h3>
<div class="p">
<sup>1</sup>St. John's Institute of Dermatology, Guy's &amp; St. Thomas' NHS Foundation Trust and King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Powell%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Kingsley Powell</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sagoo%20MK%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Manpreet K Sagoo</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Manpreet K Sagoo</span></h3>
<div class="p">
<sup>1</sup>St. John's Institute of Dermatology, Guy's &amp; St. Thomas' NHS Foundation Trust and King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sagoo%20MK%22%5BAuthor%5D" class="usa-link"><span class="name western">Manpreet K Sagoo</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ye%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Weiyu Ye</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Weiyu Ye</span></h3>
<div class="p">
<sup>1</sup>St. John's Institute of Dermatology, Guy's &amp; St. Thomas' NHS Foundation Trust and King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ye%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Weiyu Ye</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Naylor%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Ann Naylor</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Ann Naylor</span></h3>
<div class="p">
<sup>4</sup>Patient and Public Involvement Advisory Group, JAKPPPOT Trial, King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Naylor%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Ann Naylor</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Moorhead%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western">Lucy Moorhead</span></a><div hidden="hidden" id="id11">
<h3><span class="name western">Lucy Moorhead</span></h3>
<div class="p">
<sup>1</sup>St. John's Institute of Dermatology, Guy's &amp; St. Thomas' NHS Foundation Trust and King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Moorhead%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lucy Moorhead</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pink%20AE%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Andrew E Pink</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Andrew E Pink</span></h3>
<div class="p">
<sup>1</sup>St. John's Institute of Dermatology, Guy's &amp; St. Thomas' NHS Foundation Trust and King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Pink%20AE%22%5BAuthor%5D" class="usa-link"><span class="name western">Andrew E Pink</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Woolf%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Richard Woolf</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Richard Woolf</span></h3>
<div class="p">
<sup>1</sup>St. John's Institute of Dermatology, Guy's &amp; St. Thomas' NHS Foundation Trust and King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Woolf%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Richard Woolf</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Barker%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Jonathan Barker</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Jonathan Barker</span></h3>
<div class="p">
<sup>1</sup>St. John's Institute of Dermatology, Guy's &amp; St. Thomas' NHS Foundation Trust and King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Barker%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jonathan Barker</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Galloway%20JB%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">James B Galloway</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">James B Galloway</span></h3>
<div class="p">
<sup>5</sup>Centre for Rheumatic Disease, Kings College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Galloway%20JB%22%5BAuthor%5D" class="usa-link"><span class="name western">James B Galloway</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cro%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Suzie Cro</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Suzie Cro</span></h3>
<div class="p">
<sup>6</sup>Clinical Trial Statistics, Imperial College London Faculty of Medicine, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cro%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Suzie Cro</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22K%20Mahil%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Satveer K Mahil</span></a><div hidden="hidden" id="id17">
<h3><span class="name western">Satveer K Mahil</span></h3>
<div class="p">
<sup>1</sup>St. John's Institute of Dermatology, Guy's &amp; St. Thomas' NHS Foundation Trust and King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22K%20Mahil%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Satveer K Mahil</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Smith%20CH%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western">C H Smith</span></a><div hidden="hidden" id="id18">
<h3><span class="name western">C H Smith</span></h3>
<div class="p">
<sup>1</sup>St. John's Institute of Dermatology, Guy's &amp; St. Thomas' NHS Foundation Trust and King’s College London, London, UK</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Smith%20CH%22%5BAuthor%5D" class="usa-link"><span class="name western">C H Smith</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff1">
<sup>1</sup>St. John's Institute of Dermatology, Guy's &amp; St. Thomas' NHS Foundation Trust and King’s College London, London, UK</div>
<div id="aff2">
<sup>2</sup>Centre for Adherence Research and Education, King’s College London, London, UK</div>
<div id="aff3">
<sup>3</sup>Psoriasis Association, Northampton, Northamptonshire, UK</div>
<div id="aff4">
<sup>4</sup>Patient and Public Involvement Advisory Group, JAKPPPOT Trial, King’s College London, London, UK</div>
<div id="aff5">
<sup>5</sup>Centre for Rheumatic Disease, Kings College London, London, UK</div>
<div id="aff6">
<sup>6</sup>Clinical Trial Statistics, Imperial College London Faculty of Medicine, London, UK</div>
<div class="author-notes p">
<div class="fn" id="fn1"><p>Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p></div>
<div class="fn" id="fn5"><p>DG has received educational support from Lilly. HM works for the Psoriasis Association, a charity, and has received funding and/or speaker honoraria from Almirall, Abbvie, Dermal Laboratories, UCB, Janssen, Novartis, BMS, Boehringer Ingelheim and Medac Pharma. JBG has received speaker or advisory work fees from AbbVie, Alfasigma, Galapagos, Lilly, Pfizer and UCB and grant funding from AbbVie, Galapagos, Gilead, Glaxo-Smith Klein, Janssen-Cilag, Novartis, Pfizer, Sanofi, Takeda and UCB. LM has attended conferences, spoken at meetings and attended advisory boards for the following companies: Abbvie, Almirall, BMS, Galderma, Janssen Cilag, Leo, Lilly, Novartis, Sanofi, Pfizer and UCB. AEP has acted as investigator, advisor, speaker and/or received research or educational funding from Abbvie, Pfizer, Lilly, Amgen, Sanofi, Leo, Galderma, Janssen, Almirall, Novartis, BMS, UCB and BI. RW has been a consultant, advisory board member, investigator and/or speaker and received travel support for participation in congresses and/or (speaker) honoraria and/or research grants from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galderma, Incyte, Janssen-Cilag, LEO Pharma A/S, Novartis, Pfizer, Sanofi and UCB. JB has attended advisory boards and/or received consultancy fees and/or spoken at sponsored symposia, and/or received grant funding from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Meyers-Squibb, Johnson and Johnson, Lilly, Novartis and UCB. SKM reports departmental income from AbbVie, Almirall, Eli Lilly, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, Sanofi and UCB, outside the submitted work. CHS reports grants from a Medical Research Council-funded stratified medicine consortium with multiple industry partners (PSORT.org), grants from IMI (Horizon 2020)-funded European consortium with multiple industry partners (BIOMAP-IMI.eu, HIPPOCRATES-IMI.eu, grants from Open Targets (Wellcome Sanger Institute), and others from AbbVie, Novartis, Pfizer, Sanofi, Boehringer Ingelheim and Swedish Orphan Biovitrum, outside the submitted work and is Chair of UK guidelines on biologic therapy in psoriasis. The other authors reported no relevant disclosures.</p></div>
<div class="fn" id="cor1">
<sup>✉</sup><p class="display-inline">Dr C H Smith; <span>catherine.smith@kcl.ac.uk</span></p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Jun 10; Accepted 2025 Jul 11; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Copyright © Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY. Published by BMJ Group.</div>
<p>This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://creativecommons.org/licenses/by/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12374624  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40840981/" class="usa-link">40840981</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p>Palmoplantar pustulosis (PPP) is a rare, debilitating inflammatory skin disease involving painful pustules on the palms and soles. Janus kinase (JAK) inhibitors target pathways relevant to PPP disease biology but also confer a risk of major adverse cardiovascular events and malignancy in certain ‘at risk’ individuals; this includes those with PPP given prevalent smoking and cardiovascular risk factors in the PPP population. The feasibility of JAK inhibitor therapy for PPP requires assessment prior to a randomised controlled trial evaluation of drug efficacy and safety for this indication.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods and analysis</h3>
<p>The ‘Janus kinase inhibitors in palmoplantar pustulosis: a mixed-methods feasibility’ trial is an open-label, single-centre, single-arm, mixed-methods feasibility trial of JAK inhibition in PPP (REC reference: 24/NE/0147; ISRCTN61751241). Participants (n=20) will receive 8 weeks of treatment with the JAK inhibitor upadacitinib (‘Rinvoq’, 30 mg, once daily). Qualitative semistructured interviews (up to n=40) will be undertaken with trial participants, trial decliners and healthcare professionals. The primary outcome will be a composite assessment of feasibility across three domains: recruitment, adherence and acceptability, using a mixed-methods analysis approach. Secondary objectives include the identification of trial recruitment optimisation strategies, using the ‘Quintet Recruitment Intervention’, and the generation of an indication of effect size on disease severity (measured using the Palmoplantar Pustulosis Psoriasis Area and Severity Index) to inform future sample size calculations. Historic placebo control data from the Anakinra for Pustular Psoriasis: Response in a Controlled Trial (National Institute of Health and Social Care reference: 13/50/17; Research Ethics Commitee reference: 16/LO/0436) will be used as the effect size comparator. Study recruitment will be undertaken over a 24-month period, commencing in November 2024.</p></section><section id="sec3"><h3 class="pmc_sec_title">Ethics and dissemination</h3>
<p>This study has been approved by the Newcastle North Tyneside 2 Research Ethics Committee, 24/NE/0132. Our findings will inform the feasibility of a future adequately powered RCT evaluating the efficacy of JAK inhibitor therapy in PPP.</p></section><section id="sec4"><h3 class="pmc_sec_title">Trial registration number</h3>
<p>ISRCTN61751241.</p></section><section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> Psoriasis, Adult dermatology, Clinical trials, Feasibility Studies</p></section></section><hr class="headless">
<section class="bt xbox font-sm" id="BX1"><h2 class="obj_head">STRENGTHS AND LIMITATIONS OF THIS STUDY.</h2>
<ul class="list" style="list-style-type:disc">
<li><p>The Quintet Recruitment Intervention and use of historic placebo controls may generate generalisable knowledge on trial recruitment and delivery in rare disease research.</p></li>
<li><p>The study aim is to evaluate feasibility; future work will be required to establish the clinical effectiveness of Janus kinase inhibitor therapy in palmoplantar pustulosis.</p></li>
<li><p>This is a single-arm, single-centre study conducted in a tertiary care setting which may limit the generalisability of findings. ⁠</p></li>
</ul></section><section id="s1"><h2 class="pmc_sec_title">Background</h2>
<p> Palmoplantar pustulosis (PPP) is a rare, chronic, immune-mediated skin disease, characterised by painful, intensely inflamed skin on the palms and soles, studded with sheets of pustules. The prevalence of PPP is estimated as 6.4–89.4/100 000 population, with a higher preponderance in Asia, and among females.<a href="#R1" class="usa-link" aria-describedby="R1"><sup>1</sup></a> It typically presents in middle age and is closely associated with a history of smoking.<a href="#R2" class="usa-link" aria-describedby="R2"><sup>2</sup></a></p>
<p>Conventional systemic and targeted biologic immunomodulatory therapies display limited efficacy in PPP, posing a significant therapeutic challenge, and there are no currently licensed treatments for PPP in the UK.<a href="#R3" class="usa-link" aria-describedby="R3"><sup>3</sup></a> Transcriptomic studies have identified strong T2-mediated and T17-mediated inflammatory signatures in the pathogenesis of PPP.<a href="#R4" class="usa-link" aria-describedby="R4"><sup>4</sup></a> The simultaneous activation of multiple immune pathways may account for the limited therapeutic efficacy of targeted biologic therapies in this condition.</p>
<p>Janus kinase (JAK) inhibitors are a novel class of targeted immunomodulators that are increasingly used in medical specialities, including rheumatology (eg, psoriatic arthritis), gastroenterology (eg, ulcerative colitis), and dermatology (eg, atopic eczema).<a href="#R5" class="usa-link" aria-describedby="R5"><sup>5</sup></a> JAK inhibitors exert broad immunosuppressive effects via pleiotropic inhibitory effects across several intracellular inflammatory cascades, providing a strong potential rationale for their use in PPP. Consistent with this are case reports and case series supporting their potential as a therapeutic option in PPP, with a recent critical appraisal of the literature identifying 39 cases of near/complete skin clearance following treatment with different JAK inhibitors.<a href="#R6" class="usa-link" aria-describedby="R6"><sup>6</sup></a> However, there is currently a lack of trial evidence to support this management approach in PPP.</p>
<p>Given the growing clinical evidence and a plausible scientific underpinning to support the use of JAK inhibitors as a treatment for PPP, further investigation in a trial setting is warranted. However, the feasibility of an adequately powered definitive randomised controlled trial (RCT) assessing the efficacy of JAK inhibitor therapy in PPP is unclear, due to several key challenges.</p>
<p>The first challenge relates to recent safety concerns regarding JAK inhibitor therapy following a randomised, open-label, non-inferiority, post-authorisation trial of 2911 patients with rheumatoid arthritis. This study evaluated the safety and efficacy of the JAK inhibitor tofacitinib compared with tumour necrosis factor (TNF) inhibitor therapy in patients with rheumatoid arthritis who were 50 years of age or older and had at least one additional cardiovascular risk factor.<a href="#R7" class="usa-link" aria-describedby="R7"><sup>7</sup></a> During a median follow-up of 4 years, the incidence of major adverse cardiovascular events (MACEs) was higher with combined tofacitinib (3.4%; 98 patients) than with a TNF inhibitor (2.5%; 37 patients). Non-inferiority of tofacitinib compared with TNF inhibitor therapy was not shown (HR, 1.33; 95% CI: 0.91 to 1.94), because the upper boundary of the 95% CI was more than 1.8 (the pretrial stated non-inferiority cut-off). Similarly, the incidence of cancers (excluding non-melanoma skin cancer) was higher with tofacitinib (4.2%; 122 patients) than with a TNF inhibitor (2.9%; 42 patients). Non-inferiority of tofacitinib compared with TNF inhibitor therapy was not shown (HR, 1.48; 95% CI, 1.04 to 2.09), with the upper boundary of the 95% CI more than 1.8 again.</p>
<p>Tofacitinib is a pan-JAK inhibitor, and it is not currently known how these safety signals relate to more selective JAK inhibitors, such as upadacitinib (a JAK-1 selective inhibitor). A recent meta-analysis found that there was no increased risk of malignancy associated with JAK inhibitor use when compared with placebo, highlighting the need for further research and long-term follow-up safety data in this area.<a href="#R8" class="usa-link" aria-describedby="R8"><sup>8</sup></a> Nonetheless, the recent safety concerns have prompted the introduction of new guidance from regulatory bodies cautioning the use of JAK inhibitors in at-risk populations (age <span class="text-underline">&gt;</span>65 years; current or long-term former smokers; those with other cardiovascular or malignancy risk factors).<a href="#R9" class="usa-link" aria-describedby="R9"><sup>9</sup></a></p>
<p>These safety signals are highly relevant in the context of PPP. The prevalence estimate of smoking among the PPP population is 78.2%, and cumulative pack-year history and longer duration of smoking are associated with a greater risk of disease development.<a href="#R10" class="usa-link" aria-describedby="R10"><sup>10</sup></a> The current regulatory framework means that JAK inhibitors may be relatively contraindicated in a substantial proportion of people with PPP, and both clinicians and people with PPP may be reluctant to use JAK inhibitors in light of these potential risks. Therefore, successful participant recruitment to an RCT may thus be difficult to achieve.</p>
<p>This recruitment challenge is especially pertinent given PPP is a rare disease. Poor trial recruitment is a prominent issue in the study of rare diseases, leading to research failure and increased costs. Only half of publicly funded trials in the UK between 1997 and 2020 achieved their original recruitment target, and a third required an extension.<a href="#R11" class="usa-link" aria-describedby="R11"><sup>11</sup></a> Given these recruitment challenges and acceptability concerns, a feasibility assessment of the use of JAK inhibitor therapy in PPP is warranted prior to a definitive adequately powered RCT.</p>
<p>Poor medication adherence is also a prevalent issue in chronic diseases. It is estimated that roughly 50% of patients with a chronic disease do not take their medication as prescribed.<a href="#R12" class="usa-link" aria-describedby="R12"><sup>12</sup></a> Given the acceptability concerns highlighted, an exploration of adherence in this context is warranted, especially considering the high cost of JAK inhibitors.</p>
<p>An exploratory feasibility trial also provides the opportunity to explore innovative trial recruitment and efficiency strategies, such as the Quintet Recruitment Intervention (QRI).<a href="#R13" class="usa-link" aria-describedby="R13"><sup>13</sup></a> This two-phase, recruitment-focussed, quality improvement methodology has been used in at least 23 studies since 2016, ranging from surgery through to oncology, and in both feasibility and definitive trial settings. It has yet to be used in an inflammatory disease trial, or in dermatology, and PPP provides an exemplar rare disease in which to trial this approach.</p>
<p>Another strategy to enhance trial efficiency is the use of historic controls. Historic controls are individuals studied in a previous trial used as a comparison group in a future study that has no control group.<a href="#R14" class="usa-link" aria-describedby="R14"><sup>14</sup></a> Reusing data from the placebo arms of previous RCTs offers the potential to minimise risks, cost and inconvenience by reducing enrolment time, decreasing participant numbers, minimising potential bias due to dropout, accelerating trial completion and thus reducing time to treatment approval.<a href="#R15" class="usa-link" aria-describedby="R15"><sup>15</sup></a> Historic placebo controls have yet to be used more widely in the context of inflammatory diseases. We will pilot the use of historic controls in this setting, incorporating historic control data from the placebo group of the Anakinra for Pustular Psoriasis: Response in a Controlled Trial (APRICOT) as the comparator group. The APRICOT investigated the use of anakinra in the management of PPP against a placebo control and was conducted from 2015 to 2020.<a href="#R16" class="usa-link" aria-describedby="R16"><sup>16</sup></a> We have followed guidance from a recently published roadmap on the use of historic controls, mirroring the APRICOT processes and eligibility criteria in the proposed trial, ensuring the robustness of this approach.<a href="#R17" class="usa-link" aria-describedby="R17"><sup>17</sup></a></p></section><section id="s2"><h2 class="pmc_sec_title">Objective</h2>
<p>The ‘Janus kinase inhibitors in palmoplantar pustulosis: a mixed-methods feasibility (JAKPPPOT)’ trial is an open-label, single-arm study which aims to determine the feasibility of JAK inhibitor therapy in PPP, via a composite, mixed-methods assessment of three domains: recruitment, adherence and acceptability. This study will provide an indication of effect size using historical control data from the APRICOT study and will identify trial optimisation strategies to bolster the recruitment in a definitive trial.<a href="#R16" class="usa-link" aria-describedby="R16"><sup>16</sup></a></p></section><section id="s3"><h2 class="pmc_sec_title">Methods</h2>
<p>This protocol has been prepared and reported in accordance with the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidance.<a href="#R18" class="usa-link" aria-describedby="R18"><sup>18</sup></a> The trial SPIRIT checklist is available (<a href="#SP1" class="usa-link">online supplemental file 1</a>).</p>
<section id="s3-1"><h3 class="pmc_sec_title">Study design</h3>
<p>JAKPPPOT is an open-label, single-arm, mixed-methods feasibility trial, conducted at St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, UK (<a href="#F1" class="usa-link">figure 1</a>). Participants (n=20) will receive 8 weeks of treatment with the JAK inhibitor upadacitinib (‘Rinvoq’, 30 mg, once-a-day). Integrated qualitative semistructured interviews (up to n=40) will be undertaken with trial participants, trial decliners and healthcare professionals. Recruitment optimisation strategies will be identified and implemented via the QRI process incorporated into this trial. The study endpoint is 20 participants successfully recruited, or 24 months elapsing, whichever occurs first.</p>
<figure class="fig xbox font-sm" id="F1"><h4 class="obj_head">Figure 1. Overview of the JAKPPPOT study design. JAKi, Janus kinase inhibitor; JAKPPPOT, Janus kinase inhibitors in palmoplantar pustulosiAnus Kinase inhibitors in PalmoPlantar PustulOsis: a mixed-methods feasibility; PPP, palmoplantar pustulosis; QRI, Quintet Recruitment Intervention.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374624_bmjopen-15-8-g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f755/12374624/84bb080707e1/bmjopen-15-8-g001.jpg" loading="lazy" height="309" width="692" alt="Figure 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/F1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section><section id="s3-2"><h3 class="pmc_sec_title">Study population</h3>
<p>The study population is adult patients (≥18 years) with a dermatologist-confirmed diagnosis of PPP requiring systemic immunomodulatory therapy. The full inclusion and exclusion criteria are listed in <a href="#T1" class="usa-link">table 1</a>. In line with the Medicines and Healthcare products Regulatory Agency’s (MHRA) recent advice, upadacitinib will only be used in the following cohorts if no suitable treatment alternatives are available<a href="#R9" class="usa-link" aria-describedby="R9"><sup>9</sup></a>:</p>
<section class="tw xbox font-sm" id="T1"><h4 class="obj_head">Table 1. Inclusion and exclusion criteria.</h4>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th valign="bottom" rowspan="1" colspan="1">Inclusion criteria</th>
<th valign="bottom" rowspan="1" colspan="1">Exclusion criteria</th>
</tr></thead>
<tbody><tr>
<td align="left" valign="top" rowspan="1" colspan="1">
<ol class="list" style="list-style-type:decimal">
<li><p>Adults (18 years and over) with a diagnosis of palmoplantar pustulosis<a href="#T1_FN1" class="usa-link"><sup>*</sup></a> made by a trained dermatologist with disease of sufficient impact and severity to require systemic therapy</p></li>
<li><p>Disease duration of ≥6 months, not responding to an adequate trial of topical therapy including very potent corticosteroids</p></li>
<li><p>Evidence of active pustulation on palms and/or soles</p></li>
<li><p>At least moderate disease based on a Palmoplantar Pustulosis Investigator Global Assessment</p></li>
<li><p>Able to give written, informed consent to participate</p></li>
<li><p>Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.</p></li>
</ol>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<ol class="list" style="list-style-type:decimal">
<li><p>A history of malignancy of any organ system (other than treated, localised non-melanoma skin cancer), treated or untreated, within the past 5 years</p></li>
<li><p>A history of provoked or unprovoked venous thromboembolism (deep vein thrombosis or pulmonary embolism), unless actively treated with long-term anticoagulation</p></li>
<li><p>Previous systemic treatment with a JAK inhibitor</p></li>
<li><p>A history of recurrent bacterial, fungal or viral infections which, in the opinion of the principal investigator, present a risk to the patient</p></li>
<li><p>Evidence of active infection or untreated latent tuberculosis</p></li>
<li><p>HIV positive</p></li>
<li><p>Active or untreated Hepatitis B or C</p></li>
<li><p>Use of therapies with potential or known efficacy in psoriasis during or within the specified timeframe before treatment initiation as listed in the washout section</p></li>
<li><p>Moderate renal impairment (CrCl &lt; 50 mL/min)</p></li>
<li><p>Neutropenia (&lt;1.5×10<sup>9</sup>/L)</p></li>
<li><p>Thrombocytopenia (&lt;150×10<sup>9</sup>/L)</p></li>
<li><p>Moderate hepatic disease and/or raised hepatic transaminases (ALT/AST) &gt; 2 x upper limit of normal at baseline. Patients who fail this screening criterion may still be considered following review by a hepatologist and confirmed expert opinion that study entry is clinically appropriate.</p></li>
<li><p>Live vaccinations within 3 months prior to the start of study medication, and no planned live vaccinations during the trial and up to 3 months following last dose</p></li>
<li><p>Women who are pregnant, breast feeding or of childbearing potential not on adequate contraception</p></li>
<li><p>Male participants who are not willing to use highly effective methods of contraception when engaging in sexual activity with a female of childbearing potential</p></li>
<li><p>Any condition where, in the opinion of the investigator, the investigational medical product would present risk to the patient.</p></li>
<li><p>Unable to give written, informed consent.</p></li>
<li><p>Unable to comply with the study visit schedule</p></li>
<li><p>Known hypersensitivity to upadacitinib and/or its excipients (SmPC 6.1)</p></li>
<li>
<p>Receipt of any of the following within the specified timeframe before treatment initiation (baseline, visit 1):</p>
<ol class="list" style="list-style-type:lower-alpha">
<li><p>Topical treatments likely to impact signs and symptoms of psoriasis (eg, potent/very potent corticosteroids, vitamin D analogues, calcineurin inhibitors) within 2 weeks</p></li>
<li><p>Systemic immunosuppressants (eg, methotrexate, ciclosporin, acitretin) within 4 weeks</p></li>
<li><p>Phototherapy (UVB TL01, UVB, PUVA, UVA1) within 4 weeks</p></li>
<li><p>Etanercept or adalimumab within 4 weeks</p></li>
<li><p>Other biologic therapies (infliximab, certolizumab, ustekinumab, secukinumab, ixekizumab, risankizumab, bimekizumab, brodalumab, tildrakizumab, guselkumab) within 3 months</p></li>
<li><p>Other investigational drugs within 4 months or five half-lives (whichever is longer)</p></li>
<li><p>Other immunosuppressant/immunomodulatory therapies including intra-articular steroids within 30 days or five half lives (whichever is longer)</p></li>
</ol>
</li>
</ol>
</td>
</tr></tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="T1_FN1">
<sup>*</sup><p class="display-inline">Different forms of psoriasis can co-present together (eg, chronic plaque psoriasis, acrodermatitis of Hallopeau, generalised pustular psoriasis). A concomitant diagnosis of a different type of psoriasis will not be a contraindication to eligibility.</p>
</div>
<div class="fn" id="fn4"><p>ALT, alanine aminotransferase; AST, aspartate aminotransferase; CrCl, creatinine clearance; SmPC, summary of product characteristics.</p></div>
</div></section><ol class="list" style="list-style-type:decimal">
<li><p>Age 65 years or older.</p></li>
<li><p>Patients with a history of atherosclerotic cardiovascular disease or other cardiovascular risk factors (such as past long-term smokers).</p></li>
<li><p>Patients with malignancy risk factors (eg, current malignancy or history of malignancy).</p></li>
</ol>
<p>Any decision to treat patients in these cohorts will be made following discussion with the chief investigator and will be based on individualised patient factors.</p></section><section id="s3-3"><h3 class="pmc_sec_title">Intervention</h3>
<p>Participants will receive 8 weeks of treatment with upadacitinib (‘Rinvoq’, 30 mg, once daily, oral tablet). In certain patient cohorts, outlined in Section 4.4 of the summary of product characteristics, the investigational medical product (IMP) dose may be moderated to 15 mg, once daily, oral tablet. These cohorts include patients at higher risk of venous thromboembolic events, MACEs and malignancy. Any decision to reduce the dose will be made following a discussion with the chief investigator.</p>
<p>Upadacitinib has been selected as the exemplar JAK inhibitor of choice for this trial. Upadacitinib is a JAK1 inhibitor, with some JAK2 inhibition, which shows good efficacy in the management of atopic eczema (an IL-4/T2-mediated disease).<a href="#R19" class="usa-link" aria-describedby="R19"><sup>19</sup></a> Its inhibitory action across both JAK1- and JAK2-mediated pathways provides a strong mechanistic rationale for its use in PPP.<a href="#R4" class="usa-link" aria-describedby="R4"><sup>4</sup></a> To date, there have been over 50 reported cases indicating the efficacy of upadacitinib in PPP, contributing to a growing clinical interest in its use.<a href="#R20" class="usa-link" aria-describedby="R20"><sup>20 21</sup></a> The findings of this study will inform the decision regarding drug choice for a future definitive RCT.</p></section><section id="s3-4"><h3 class="pmc_sec_title">Comparator</h3>
<p>Retrospective placebo-controlled data from the APRICOT (National Institute of Health and Social Care Research [NIHR]reference: 13/50/17; Research Ethics Committee [REC] number: 16/LO/0436; International Standard Registered Clinical/soCial sTudy Number [ISRCTN] number: ISCRTN13127147) will be used to generate an indication of effect size for the purpose of estimating the required sample size of a definitive RCT.<a href="#R16" class="usa-link" aria-describedby="R16"><sup>16</sup></a> Placebo controls in the APRICOT previously received 0.67 mL of vehicle solution daily through self-administered subcutaneous injection over 8 weeks. The IMP in APRICOT was anakinra (Kineret; SOBI, Stockholm, Sweden; 100 mg/0.67 mL daily delivered via self-administered subcutaneous injection).</p></section><section id="s3-5"><h3 class="pmc_sec_title">Outcomes</h3>
<section id="s3-5-1"><h4 class="pmc_sec_title">Primary outcomes</h4>
<p>The following outcomes will be assessed after 24 months of recruitment, or when the recruitment target of 20 participants is achieved (whichever occurs first):</p>
<ol class="list" style="list-style-type:decimal">
<li>
<p>Overall proportion of potential participants identified who enrolled in the trial, termed the ‘recruitment rate’.</p>
<ul class="list" style="list-style-type:disc"><li><p>‘Potential participants identified’ is defined as those who have direct contact with the research team.</p></li></ul>
</li>
<li>
<p>Overall proportion of participants achieving ‘good adherence’ (proportion of days covered &gt;80%) during the trial.</p>
<ul class="list" style="list-style-type:disc"><li><p>‘Proportion of days covered’ is defined as the total medication taken during the 8-week trial period as a proportion of the total medication dispensed.</p></li></ul>
</li>
<li>
<p>Overall proportion of participants who view JAK inhibitor therapy in PPP to be ‘acceptable’.</p>
<ul class="list" style="list-style-type:disc">
<li><p>Acceptability will be measured based on responses to the following question at the end of the 8-week treatment period: ‘Overall, how acceptable was taking upadacitinib to you?’</p></li>
<li><p>A 5-point Likert scale will be used, with answers dichotomised into acceptable (acceptable/completely acceptable) or unacceptable (completely unacceptable/unacceptable/neutral)</p></li>
</ul>
</li>
</ol></section><section id="s3-5-2"><h4 class="pmc_sec_title">Secondary outcomes</h4>
<p>The following outcomes will be assessed after 24 months of recruitment, or when the recruitment target of 20 participants is achieved (whichever occurs first):</p>
<ol class="list" style="list-style-type:decimal">
<li><p>Total number of potential identified participants who have contact with the research team.</p></li>
<li><p>Speed of participant identification (participants identified/month).</p></li>
<li><p>Speed of participant recruitment (participants identified/month).</p></li>
<li><p>Total number of ineligible participants.</p></li>
<li><p>Reasons for ineligibility.</p></li>
<li><p>Recruitment of 20 participants within 24 months.</p></li>
<li><p>Overall mean change in Palmoplantar Pustulosis-Psoriasis Area and Severity Index (PP-PASI) over the 8-week treatment period, adjusted for baseline PP-PASI.<a href="#R22" class="usa-link" aria-describedby="R22"><sup>22</sup></a></p></li>
<li><p>Placebo control data from the APRICOT (2015–2020, n=31 with complete data) will be used as a comparator.</p></li>
</ol>
<p>The following outcome is assessed at the end of each phase of the QRI approach (new phase for every 20 eligible patient participants approached throughout the trial):</p>
<ul class="list" style="list-style-type:none"><li>
<span class="label">8</span><p class="display-inline">Change in recruitment rate with each phase of the QRI approach.</p>
</li></ul></section><section id="s3-5-3"><h4 class="pmc_sec_title">Exploratory outcomes</h4>
<p>The following outcomes are assessed after 24 months of recruitment, or when the recruitment target of 20 participants is achieved (whichever occurs first):</p>
<ol class="list" style="list-style-type:decimal">
<li>
<p>Evaluation of trial recruitment diversity and inclusion.</p>
<ul class="list" style="list-style-type:disc"><li><p>Participant demographics will include age, sex, ethnicity and socioeconomic background.</p></li></ul>
</li>
<li>
<p>Accuracy of disease severity assessments of photographs compared to in-person assessments.</p>
<ul class="list" style="list-style-type:disc"><li><p>PP-PASI and Palmoplantar Pustulosis-Investigator Global Assessment (PPP-IGA) grading of photographs will be compared with in-person disease severity assessments.</p></li></ul>
</li>
<li>
<p>Overall mean change in total pustule count over the 8-week treatment period, compared to baseline adjusted for baseline total pustule count.</p>
<ul class="list" style="list-style-type:disc"><li><p>Placebo control data from the APRICOT (2015–2020, n=31 with complete data) will be used as a comparator.</p></li></ul>
</li>
<li>
<p>Overall mean change in fresh pustule count over the 8-week treatment period, compared to baseline adjusted for baseline fresh pustule count.</p>
<ul class="list" style="list-style-type:disc"><li><p>Placebo control data from the APRICOT (2015–2020, n=31 with complete data) will be used as a comparator.</p></li></ul>
</li>
<li>
<p>Overall proportion of participants achieving clearance of PPP over the 8-week treatment period.</p>
<ul class="list" style="list-style-type:disc">
<li><p>Clearance will be defined as a PPP-IGA of 0/1.</p></li>
<li><p>Placebo control data from the APRICOT (2015–2020, n=31 with complete data) will be used as a comparator.</p></li>
</ul>
</li>
<li>
<p>Overall mean change in chronic plaque psoriasis severity (if applicable) over the 8-week treatment period, adjusted for baseline chronic plaque psoriasis severity.</p>
<ul class="list" style="list-style-type:disc">
<li><p>Severity will be assessed using the PASI.<a href="#R23" class="usa-link" aria-describedby="R23"><sup>23</sup></a></p></li>
<li><p>Placebo control data from the APRICOT (2015–2020, n=16 with complete data) will be used as a comparator.</p></li>
</ul>
</li>
<li>
<p>Overall mean change in participants’ symptoms and quality of life over the 8-week treatment period, adjusted for baseline. Dermatology Life Quality Index, Patient Global Assessment and European Quality of Life 5 Dimensions 5 Level Version (EQ5D-5L) will be used to assess participants’ symptoms and quality of life</p>
<ul class="list" style="list-style-type:disc"><li><p>Placebo control data from the APRICOT (2015–2020, n=31 with complete data) will be used as a comparator.</p></li></ul>
</li>
<li>
<p>Overall proportion of participants achieving a 50% reduction in PP-PASI score (PPPASI50) over the 8-week treatment period, compared to baseline (visit 1).</p>
<ul class="list" style="list-style-type:disc"><li><p>Placebo control data from the APRICOT (2015–2020, n=31 with complete data) will be used as a comparator.</p></li></ul>
</li>
</ol></section></section><section id="s3-6"><h3 class="pmc_sec_title">Adverse events monitoring</h3>
<p>Adverse events will be tabulated and described for all subjects who received at least one dose of study medication. Adverse events will be summarised by event type, including information on the number with at least one event and the number of events to account for recurrent events.</p></section><section id="s3-7"><h3 class="pmc_sec_title">Sample size rationale</h3>
<p>We will aim to recruit 20 participants, in keeping with other published feasibility studies.<a href="#R24" class="usa-link" aria-describedby="R24"><sup>24 25</sup></a> Over a 24-month recruitment period, we anticipate approaching a total of around 100 potentially eligible individuals. Based on previous experience, we anticipate that the actual recruitment rate would be no less than 20%, so this would provide us with at least 20 participants.</p>
<p>With 100 approached participants, if 20 (20%) are recruited into the trial, this would allow us to estimate the 95% CI for the recruitment rate with precision of at least ±8%. Assuming 75% of participants adhere to treatment at least 80% of the time (as observed in APRICOT), a sample size of 20 participants would allow us to estimate ≥80% treatment adherence with a 95% CI: 51% to 91%. With 20 participants on treatment, JAKPPPOT will estimate a PPPASI50 in the JAK inhibitor arm with precision of at least ±3.43 PP-PASI points. This is based on figures derived from the APRICOT (mean baseline PP-PASI: 17.8; SD for the PP-PASI change at 8 weeks in active arm: 7.32).<a href="#R16" class="usa-link" aria-describedby="R16"><sup>16</sup></a> A PPPASI50 is an outcome that has been analysed as a primary/secondary endpoint in several PPP trials and was described as ‘treatment success’ during patient and public involvement (PPI) discussions with people with PPP.<a href="#R26" class="usa-link" aria-describedby="R26"><sup>26</sup></a> The PP-PASI reduction in the treatment arm will inform the sample size calculation for a larger definitive trial.</p></section><section id="s3-8"><h3 class="pmc_sec_title">Progression criteria and rationale</h3>
<p>Progression criteria have been outlined to determine whether it is appropriate to progress to a subsequent adequately powered RCT, shown in <a href="#T2" class="usa-link">table 2</a>. Findings from the primary and secondary quantitative outcomes will be incorporated with the qualitative findings to inform decisions regarding an ‘intermediate’ results in any domain (ie, upgrade to feasible or downgrade to non-feasible). All recommendations will be reviewed by the trial steering committee (TSC). For criteria judged to be intermediate or non-feasible, the study team will examine the likely causes and consider whether a mitigation strategy could be successfully implemented.</p>
<section class="tw xbox font-sm" id="T2"><h4 class="obj_head">Table 2. Progression criteria for the JAKPPPOT trial.</h4>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th valign="bottom" rowspan="1" colspan="1">Domain</th>
<th valign="bottom" rowspan="1" colspan="1">Non-feasible</th>
<th valign="bottom" rowspan="1" colspan="1">Intermediate</th>
<th valign="bottom" rowspan="1" colspan="1">Feasible</th>
</tr></thead>
<tbody>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Recruitment:<br>proportion of potential participants identified who enrolled in the trial</td>
<td align="left" valign="top" rowspan="1" colspan="1">&lt;20%</td>
<td align="left" valign="top" rowspan="1" colspan="1">20–40%</td>
<td align="left" valign="top" rowspan="1" colspan="1">&gt;40%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Adherence:<br>proportion of participants achieving ‘Good’ adherence (&gt;80% of medication taken as prescribed)</td>
<td align="left" valign="top" rowspan="1" colspan="1">&lt;20%</td>
<td align="left" valign="top" rowspan="1" colspan="1">20–80%</td>
<td align="left" valign="top" rowspan="1" colspan="1">&gt;80%</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Acceptability:<br>proportion of participants who view JAK inhibitor therapy in PPP to be ‘acceptable’</td>
<td align="left" valign="top" rowspan="1" colspan="1">&lt;20%</td>
<td align="left" valign="top" rowspan="1" colspan="1">20–80%</td>
<td align="left" valign="top" rowspan="1" colspan="1">&gt;80%</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fn5_pmc"><p>JAK, Janus kinase; JAKPPPOT, Janus kinase inhibitors in palmoplantar pustulosis: a mixed-methods feasibility; PPP, palmoplantar pustulosis.</p></div></div></section></section><section id="s3-9"><h3 class="pmc_sec_title">Recruitment</h3>
<p>A low recruitment rate is assumed, in line with the APRICOT study (17% overall recruitment rate).<a href="#R16" class="usa-link" aria-describedby="R16"><sup>16</sup></a> Factors in favour of a higher recruitment rate than the APRICOT are the single-arm trial design and the use of an oral tablet medication versus a daily subcutaneous injection with a high burden of injection site reactions. Factors negatively impacting recruitment are that this is a feasibility study rather than an efficacy study, there is no associated open-label extension and the potential side effect profile of upadacitinib. Optimisation strategies will be implemented through the trial to improve recruitment.</p>
<p>Secondary quantitative outcomes will be incorporated into the feasibility assessment, for example, failure to recruit 20 participants within 24 months would be an indicator of non-feasibility. If recruitment cannot be achieved in the context of an open-label trial, it is strong evidence against the feasibility of an adequately powered RCT.</p></section><section id="s3-10"><h3 class="pmc_sec_title">Adherence</h3>
<p>Adherence will be assessed by counting any remaining medication via inspection of medication packaging at the end of each 4-week period (visit 3 and visit 4) to determine the proportion of days covered (total medication taken/total medication dispensed). If the packaging is unavailable, participants’ responses to the Voils DOSE-Nonadherence measure will be used as a surrogate.<a href="#R27" class="usa-link" aria-describedby="R27"><sup>27</sup></a></p>
<p>A high adherence rate is expected for several reasons. The tablet is easy to administer, and there is a relatively high burden of clinic visits over the 8-week treatment period. This will remind participants to take the medication and allow any compliance issues to be identified and addressed quickly.</p>
<p>Previous studies have demonstrated an association between an adherence rate of &gt;80% and improved outcomes, when compared with an adherence rate of &lt;80%, in certain disease contexts (eg, following a myocardial infarction).<a href="#R28" class="usa-link" aria-describedby="R28"><sup>28 29</sup></a> An 80% adherence threshold is often used, therefore, as a key measure of adherence in the context of clinical trials.<a href="#R30" class="usa-link" aria-describedby="R30"><sup>30</sup></a></p>
<p>The optimal threshold for adherence will differ depending on the specific disease, medication and population in question. Given the paucity of current literature regarding the use of upadacitinib in the management of PPP, it is not currently possible to determine the necessary adherence threshold for this specific context, and so the accepted threshold of &gt;80% adherence rate has been used.<a href="#R30" class="usa-link" aria-describedby="R30"><sup>30</sup></a> Given the small numbers of trial participants, a wide intermediate progression criteria window has been specified, allowing findings from the integrated qualitative study to be incorporated into the analysis.</p></section><section id="s3-11"><h3 class="pmc_sec_title">Acceptability</h3>
<p>The recent safety concerns regarding the use of this drug class among those at risk of cardiovascular disease may render them unacceptable to people with PPP, a population in which smoking is prevalent.<a href="#R7" class="usa-link" aria-describedby="R7"><sup>7 31</sup></a> However, there are several factors that may mitigate these concerns. There is a growing body of evidence to support the safety and efficacy of JAK inhibitors in the management of other medical conditions, with upadacitinib well-tolerated in the context of atopic dermatitis.<a href="#R32" class="usa-link" aria-describedby="R32"><sup>32</sup></a> The ease of administration is also a factor cited by patients in support of their acceptability.<a href="#R33" class="usa-link" aria-describedby="R33"><sup>33</sup></a> Given the lack of effective treatment options available for this condition, resulting in marked unmet clinical need, participants may be more willing to consider treatment with a JAK inhibitor in spite of side effect concerns.<a href="#R3" class="usa-link" aria-describedby="R3"><sup>3</sup></a> Finally, MHRA guidance has been incorporated into the study design, ensuring those most at risk from JAK inhibitor treatment are not eligible to take part. Given the small number of trial participants, a wide intermediate progression criteria window has been specified, allowing findings from the integrated qualitative study to be incorporated into the analysis.</p></section><section id="s3-12"><h3 class="pmc_sec_title">Participant recruitment</h3>
<p>Potentially eligible trial participants will be identified via a number of means, including routine care visits, existing participants of related research studies who have consented to recall and self-referral following advertisement through national (eg, Psoriasis Association) and regional communication channels (newsletters, websites and social media). Participants can choose to participate in the trial and/or the semistructured interviews. Written, informed consent will be obtained by a physician (<a href="#SP2" class="usa-link">online supplemental file 2</a>).</p></section><section id="s3-13"><h3 class="pmc_sec_title">Study procedures</h3>
<p>The full study activities at each visit are outlined in <a href="#T3" class="usa-link">table 3</a>. The patient participant pathway consists of three periods: a screening period, a treatment period and a follow-up period. The screening period is up to a maximum of 3 months. Patients who fail the screening process may be re-screened if clinically appropriate.</p>
<section class="tw xbox font-sm" id="T3"><h4 class="obj_head">Table 3. Schedule of trial activities.</h4>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th valign="bottom" rowspan="1" colspan="1"></th>
<th valign="bottom" rowspan="1" colspan="1">Screening (&lt;3 months between screening and baseline)</th>
<th colspan="4" valign="bottom" rowspan="1">Treatment period</th>
<th valign="bottom" rowspan="1" colspan="1">Follow-up</th>
<th valign="bottom" rowspan="1" colspan="1">Safety follow-up</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="3" align="left" valign="top" colspan="1">
<strong>Allowed visit window:</strong><br><span class="text-underline"><strong>+</strong></span>
<strong>3 days</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>Visit 0</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>Visit 1</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>Visit 2</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>Visit 3</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>Visit 4</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>Visit 5</strong>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">
<strong>Visit 6</strong>
</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">Baseline</td>
<td align="left" valign="top" rowspan="1" colspan="1">(week 1)</td>
<td align="left" valign="top" rowspan="1" colspan="1">(week 4)</td>
<td align="left" valign="top" rowspan="1" colspan="1">(week 8)</td>
<td align="left" valign="top" rowspan="1" colspan="1">(week 12)</td>
<td align="left" valign="top" rowspan="1" colspan="1">(week 20)</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Study enrolment</td>
<td align="left" valign="top" rowspan="1" colspan="1">Treatment initiation</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1">Treatment end</td>
<td align="left" valign="top" rowspan="1" colspan="1">Study end</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Written informed consent</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Inclusion/exclusion eligibility check and sign-off</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Demographics</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Medical history</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Social history</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Family history</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">PPP history</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Clinical phenotyping of disease/concomitant psoriasis</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Physical examination</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Vital signs<a href="#T3_FN2" class="usa-link"><sup>*</sup></a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">PPPASI<a href="#T3_FN3" class="usa-link"><sup>†</sup></a> (×2: blinded and unblinded assessment)</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Fresh pustule count<a href="#T3_FN3" class="usa-link"><sup>†</sup></a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Total pustule count<a href="#T3_FN3" class="usa-link"><sup>†</sup></a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">PPP-IGA<a href="#T3_FN3" class="usa-link"><sup>†</sup></a> (×2: blinded and unblinded assessment)</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">PASI (plaque psoriasis only)</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">BSA</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Patient global assessment</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">DLQI</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">EQ5D-5L</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">DOSE-Nonadherence questionnaire</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Photography (palms and soles)</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">CXR<a href="#T3_FN4" class="usa-link"><sup>‡</sup></a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">T-Spot.TB<a href="#T3_FN5" class="usa-link"><sup>§</sup></a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">HIV, HBV and HCV</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Safety bloods<a href="#T3_FN6" class="usa-link"><sup>¶</sup></a><a href="#T3_FN7" class="usa-link"><sup>**</sup></a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">X<sup><a href="#T3_FN1" class="usa-link">††</a></sup>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">X<sup><a href="#T3_FN1" class="usa-link">††</a></sup>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">bHCG (blood)<a href="#T3_FN8" class="usa-link"><sup>‡‡</sup></a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Prescribing and dispensing trial IMP</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Retrieval of IMP packaging (pill count)</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Acceptability Questionnaire<a href="#T3_FN9" class="usa-link"><sup>§§</sup></a>
</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">RCT scoping question</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Concomitant meds</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Adverse events monitoring</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
</tr>
<tr><td colspan="8" align="left" valign="top" rowspan="1">
<strong>Integrated qualitative study</strong>
</td></tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Trial participant interview</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Trial decliner interview</td>
<td align="left" valign="top" rowspan="1" colspan="1">X</td>
<td align="left" valign="top" rowspan="1" colspan="1"></td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
<td align="left" valign="top" rowspan="1" colspan="1"> </td>
</tr>
<tr>
<td align="left" valign="top" rowspan="1" colspan="1">Healthcare professional interview</td>
<td colspan="7" align="left" valign="top" rowspan="1">Interviews will take place with healthcare professionals throughout the duration of the trial (maximum one interview per healthcare professional)</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/T3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="T3_FN2">
<sup>*</sup><p class="display-inline"> Vital signs include heart rate, blood pressure, oxygen saturations, respiratory rate and temperature.</p>
</div>
<div class="fn" id="T3_FN3">
<sup>†</sup><p class="display-inline">Assessed by independent blinded assessor. PPPASI and PPP-IGA were also assessed by a second assessor.</p>
</div>
<div class="fn" id="T3_FN4">
<sup>‡</sup><p class="display-inline">CXR not indicated if participant has had a CXR in the previous 12 months for clinical purposes.</p>
</div>
<div class="fn" id="T3_FN5">
<sup>§</sup><p class="display-inline">T-Spot.TB not indicated for those participants known to have been successfully treated for TB (completed the prescribed treatment courses) as screening test is not clinically indicated. If unsure, please seek specialist advice.</p>
</div>
<div class="fn" id="T3_FN6">
<sup>¶</sup><p class="display-inline">Safety bloods comprise WBC, Hb, platelet count, creatinine, urea, sodium, potassium, bilirubin, aspartate aminotransferase, alanine transaminase, HbA1c and cholesterol.</p>
</div>
<div class="fn" id="T3_FN7">
<sup>**</sup><p class="display-inline">CRP to be collected at baseline (visit 1) only.</p>
</div>
<div class="fn" id="T3_FN1">
<sup>††</sup><p class="display-inline">If the time between screening and baseline safety assessment bloods is &gt;4 weeks (ie, for participants washing out for 3 months from biologic therapy) the participant should be asked to attend for additional safety assessment blood tests. If feasible, this should be on the same day as the baseline visit allowing for time to clinically review the results before the first treatment dose (in which case only one set of baseline safety assessment bloods should be taken); however, if not convenient, it should be scheduled within 4 weeks of the baseline visit (these may be taken by their GP). If the participant attends an extra visit for these tests, then they should also go on to complete the full baseline visit, that is, repeat the baseline safety assessment bloods as scheduled.</p>
</div>
<div class="fn" id="T3_FN8">
<sup>‡‡</sup><p class="display-inline">bHCG not indicated or applicable for postmenopausal women.</p>
</div>
<div class="fn" id="T3_FN9">
<sup>§§</sup><p class="display-inline">Acceptability questionnaires will be completed during Visits 1 and 5 for participants not taking part in the integrated qualitative study (qualitative study participants will complete the questionnaires during the interviews).</p>
</div>
<div class="fn" id="fn15"><p>bHCG, beta-human chorionic gonadotropin; BSA, body surface area; CXR, chest X ray; DLQI, Dermatology Life Quality Index; EQ5D-5L, European Quality of Life 5 Dimensions 5 Level Version; Hb, haemoglobin; HBV, Hepatitis B virus; HCV, Hepatitis C virus; IMP, investigational medical product; PPP, palmoplantar pustulosis; PP-PASI, Palmoplantar Pustulosis Psoriasis Area and Severity Index; PPP-IGA, Palmoplantar Pustulosis-Investigator Global Assessment; RCT, randomised controlled trial; TB, tuberculosis.</p></div>
</div></section><p>The treatment period (visits 1–4) is 8 weeks. At the start of the treatment period, eligible patient participants will receive upadacitinib, to be administered daily as an oral tablet for 8 weeks. Participants will receive 4 weeks of medication at Visit 1 (baseline) and Visit 3 (week 4).</p>
<p>The follow-up period (visit 5) at week 12 will be used to assess disease relapse off study treatment, follow-up any adverse events and plan for post-trial management of their condition. Participants will also be asked the following question to scope out their views on a future RCT: ‘Would you be interested in participating in a trial similar to this with either a dummy arm or active comparison drug arm in the future?’. A final safety review (visit 6) will be carried out at week 20 to assess for any further adverse events.</p></section><section id="s3-14"><h3 class="pmc_sec_title">Concomitant medication</h3>
<p>Emollient therapy and mild-moderate topical corticosteroids will be permitted throughout the trial. Investigator-directed use of potent/super potent topical corticosteroids as ‘rescue’ therapy can be used if necessary, with the volume used recorded at study visits to evaluate any potential confounding effect.</p>
<p>Systemic therapies that are likely to have efficacy in PPP or to compound the immunosuppressive effects of upadacitinib are prohibited. If treatment with these is essential, the participant must notify the study team and they will be withdrawn from the trial.</p>
<p>Guidance from the clinical trials facilitation and co-ordination group will be followed regarding effective forms of contraception during the trial.</p></section><section id="s3-15"><h3 class="pmc_sec_title">Data collection and management</h3>
<p>All outcome assessments of PPP will be assessed by an independent assessor blinded to the patient participant’s position on the trial pathway (ie, screening/receiving treatment/follow-up visit) to minimise bias. They will not be involved in other aspects of the trial (eg, recruitment, qualitative interviews). There should be no need for unblinding of assessors as safety concerns will be addressed by the unblinded research team members.</p>
<p>A visit window of 3 days either side of the scheduled visit will be allowed. In the event that a visit falls outside the target visit window of +3 days, the visit should be scheduled as soon as possible, and the data should be entered into the intended visit. All visits will be carried out in person. In exceptional circumstances where a patient is unable to attend a study visit, a virtual visit will be carried out.</p>
<p>Data will be collected using a paper case report form and stored securely in an electronic data management system (CAPTURE). Personal information stored within CAPTURE that could identify individuals will remain strictly confidential. Access to the information will be restricted at all times to researchers with clear purpose or need to access it. All data held within CAPTURE is processed in accordance with the Data Protection Act 2018 and UK General Data Protection Regulation (GDPR).</p>
<p>Should a participant decide to withdraw from the trial, all efforts will be made to report the reason for withdrawal as thoroughly as possible and they will be encouraged to continue to provide outcome data. All data collected to date will be retained.</p>
<p>We will seek participant consent in the informed consent form for their de-identified study data to be shared with research collaborators running other research studies in our organisation and in other organisations.</p></section><section id="s3-16"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p>Baseline characteristics will be summarised by using suitable measures of central tendencies. For continuous data, means/medians and SD/IQR will be reported depending on the data distribution, and frequencies with proportions will be reported for categorical data. The primary feasibility outcomes will be reported as proportions with a 95% CI. No formal hypothesis testing will be conducted as this is a feasibility study. A detailed statistical analysis plan has been written for the analysis approach.</p>
<p>The mean change in PP-PASI at week 8 for the treatment arm will be estimated with a 95% CI. This analysis will follow an intention-to-treat principle and include all participants with a non-missing outcome, regardless of how much treatment was received. Every effort will be made to reduce missing data. No imputation will be made for missing data for this feasibility study. Patterns of missingness will be explored and its relationship to the outcome described.</p>
<p>For the comparison with the historical control data, the analysis model will be a linear (Gaussian) mixed effect model, using PP-PASI scores from weeks 1/4/8, adjusted for baseline PP-PASI. This model will include a random effect for participant and fixed effects for time, time-by-treatment group interaction and baseline PP-PASI.</p>
<p>Statistical analysis will be undertaken according to the latest guidelines on the use of historical controls.<a href="#R16" class="usa-link" aria-describedby="R16"><sup>16</sup></a> The trial protocol is matched to the APRICOT where possible (inclusion/exclusion criteria, study methods, measurements).<a href="#R16" class="usa-link" aria-describedby="R16"><sup>16</sup></a> The access to contemporaneous, patient-level data will enable adjustment for patients’ covariates and the involvement of a blinded assessor will mitigate the inherent risk of bias associated with an open label, single-arm design. Sensitivity analyses exploring the use of inverse probability of treatment weighting to adjust for any observed differences between the treatment cohort and the historic controls will be conducted if unbalance is observed between the treatment cohort and the historic controls to ensure the robustness of results.<a href="#R34" class="usa-link" aria-describedby="R34"><sup>34</sup></a> Given the change to the APRICOT exclusion criteria to address the recent MHRA guidance (ie, exclusion of patients over the age of 65 unless there are no suitable alternatives), a sensitivity analysis based on the subset of patients across APRICOT and JAKPPPOT who would have been eligible for both trials will be conducted if required.<a href="#R9" class="usa-link" aria-describedby="R9"><sup>9</sup></a> If previous placebo APRICOT participants are recruited into the JAKPPPOT study, an additional sensitivity analysis will be conducted, excluding their data from the APRICOT placebo cohort.</p></section><section id="s3-17"><h3 class="pmc_sec_title">Integrated qualitative study</h3>
<p>Qualitative research will be integrated into the trial to provide fundamental insights into the feasibility and design of a definitive trial. Qualitative interviews will be undertaken in the following three cohorts:</p>
<ol class="list" style="list-style-type:decimal">
<li><p>Trial participants: semistructured interviews before and after the 8-week treatment period (up to 20 interviews).</p></li>
<li><p>Trial decliners: one semistructured interview per trial decliner (up to 10 interviews). Trial decliners are individuals who have been invited to participate in the clinical trial and then declined.</p></li>
<li><p>Healthcare professionals: one semistructured interview per healthcare professional (up to 10 interviews).</p></li>
</ol>
<p>Qualitative interviews will be undertaken by an appropriate, delegated member of the research team. These interviews will be conducted either in person or online via Microsoft Teams, depending on participant preference. Interview topic guides will be used to ensure similar areas are covered with each participant, but will be sufficiently flexible to encourage the interviewees to express their own views about the study. We will aim to interview up to 10 eligible participants in each cohort, or up until data saturation has been reached (no new themes were generated after three sequential participant interviews).</p>
<p>The semistructured interviews will be recorded, transcribed verbatim and thematically analysed.<a href="#R35" class="usa-link" aria-describedby="R35"><sup>35</sup></a> Transcripts will be reviewed and coded thematically using the NVivo 15 software package, identifying key insights, experiences or opinions. Coded interviews will be reviewed and compared so as to characterise recurrent and/or prioritised ideas about the study and interventions. The perspectives of different participants will be compared and synthesised in this process in order to reflect on similar and different experiences. Analytic codes and themes will be tested and refined as new data are considered. The results will be triangulated with the other study findings to inform recommendations for implementing trial findings and the design of the future definitive RCT. Differences in prospective and retrospective acceptability will be explored via comparison between the pretrial and post-trial interview responses.<a href="#R36" class="usa-link" aria-describedby="R36"><sup>36</sup></a></p></section><section id="s3-18"><h3 class="pmc_sec_title">Quintet Recruitment Intervention</h3>
<p>The aim of the QRI is to understand the recruitment process and how it operates in the context of the trial.<a href="#R13" class="usa-link" aria-describedby="R13"><sup>13</sup></a> Sources of recruitment difficulties can then be identified and suggestions made to change aspects of the design, conduct, organisation or training that could then lead on to improvements in recruitment.</p>
<p>The aim of Phase 1 is to understand the recruitment process as it occurs. There are several distinct sources of information that can be used to identify recruitment difficulties about recruitment, as outlined in <a href="#F2" class="usa-link">figure 2</a>.</p>
<figure class="fig xbox font-sm" id="F2"><h4 class="obj_head">Figure 2. An outline of the JAKPPPOT Quintet Recruitment Intervention phases. CI, chief investigator; JAKPPPOT, Janus kinase inhibitors in palmoplantar pustulosiAnus Kinase inhibitors in PalmoPlantar PustulOsis: a mixed-methods feasibility; TMG, trial management group.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12374624_bmjopen-15-8-g002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f755/12374624/48f689750395/bmjopen-15-8-g002.jpg" loading="lazy" height="393" width="692" alt="Figure 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/F2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>Findings of the qualitative analysis from Phase 1 will be presented to the chief investigator and trial management group (TMG). During Phase 2, a plan of action will then be drawn up and implemented to optimise recruitment.</p>
<p>Previous trial adaptations identified and enacted using the QRI approach include, but are not limited to<a href="#R37" class="usa-link" aria-describedby="R37">37</a>,<a href="#R41" class="usa-link" aria-describedby="R41">41</a>:</p>
<ol class="list" style="list-style-type:decimal">
<li><p>Discussing the interpretation of eligibility criteria and equipoise with trial site clinicians.</p></li>
<li><p>Providing QRI training and support for recruiters about how to manage patient preferences.</p></li>
<li><p>Providing suggestions to change patient information leaflets and trial literature.</p></li>
<li><p>Discussing the definition of usual care with the trial team.</p></li>
<li><p>Providing training and support for recruiters about trial design and how to approach all eligible patients.</p></li>
</ol>
<p>In addition to these, possible alterations to the JAKPPPOT trial protocol that have been identified by the study team include:</p>
<ol class="list" style="list-style-type:decimal">
<li><p>Adjustment of the inclusion criteria to allow co-prescription of other conventional systemic therapies, such as methotrexate and ciclosporin, alongside upadacitinib.</p></li>
<li><p>Formal involvement of a wider clinical trials network to bolster recruitment efforts.</p></li>
<li><p>Production of a promotional video for distribution on social media platforms (eg, via the Psoriasis Association).</p></li>
<li><p>Incorporation of adherence support methods, such as a trial medication diary.</p></li>
</ol></section><section id="s3-19"><h3 class="pmc_sec_title">Equality, diversity and inclusion</h3>
<p>PPP has a strong female sex preponderance, and so it is likely that recruitment will mirror this gender imbalance (APRICOT consisted of 84% female participants). There will be no restrictions imposed on involvement in this study based on sex, disability, marital status, sexuality, ethnicity, religion or socioeconomic status. Travel costs will be covered to minimise the risk of cost being a barrier to participation.</p>
<p>The semistructured interviews will be carried out either in person or online, depending on participant preference. This has been done to ensure that potential cohorts are not excluded (eg, those with certain work commitments, language barriers and IT issues), bolstering inclusivity.</p>
<p>We will use our collaboration with the Psoriasis Association to ensure widespread publicity for this research, to ensure a representative demographic of participants is included. One of the exploratory aims of the study will be to carry out a retrospective evaluation of the study population to ensure trial recruitment diversity and inclusion can be optimised in advance of a future RCT.</p></section><section id="s3-20"><h3 class="pmc_sec_title">Patient and public involvement</h3>
<p>This trial has been designed to address the James Lind Alliance priorities for psoriasis research, including how to induce remission, treat flares and regain control.<a href="#R42" class="usa-link" aria-describedby="R42"><sup>42</sup></a> The trial design was informed by a PPI meeting with four patients with lived experience of PPP (three women, one man), and further discussions with one patient with PPP with lived experience of treatment with a JAK inhibitor. A PPI advisory panel has been established, which will meet 6-monthly throughout the trial. Participant communication materials have been co-developed with this PPI panel. Proposed changes identified as part of the QRI process will be reviewed with PPI panel members prior to implementation. The PPI panel will review emerging findings from the trial and feedback to the TMG.</p>
<p>We will advertise the trial via the Psoriasis Association, the UK’s leading member organisation for people affected by psoriasis, and invite testimonials for social media, purposefully inviting underserved groups.</p></section><section id="s3-21"><h3 class="pmc_sec_title">Ethics approval, monitoring and dissemination</h3>
<p>This study has been approved by the Newcastle North Tyneside 2 Research Ethics Committee (REC, reference 24/NE/0132) and the Health Research Authority (HRA). Any subsequent protocol amendments will be submitted to the REC and HRA for approval as appropriate.</p>
<p>Monitoring of the trial will be conducted by an independent TSC, in accordance with the MRC guidelines for Management of Global Health Trials, 2022.<a href="#R43" class="usa-link" aria-describedby="R43"><sup>43</sup></a> Given this is a small-scale, feasibility non-CTIMP (Clinical Trial of an Investigational Medicinal Product) trial using a well-established drug (upadacitinib) that has been licensed for use in the UK since 2020, the role of a data monitoring committee will be subsumed in the role of the TSC. The TSC will be comprised of an independent chair, an independent statistician, a patient representative and an independent clinical expert. No formal interim analysis with prespecified stopping guidelines will be conducted.</p>
<p>Results will be made available to healthcare professionals, patients, the funders and other researchers through scientific publications in peer-reviewed journals. We will also produce lay summaries, newsletters and infographics for distribution via the Psoriasis Association. Our PPI panel will be invited to contribute to study publications as co-authors.</p>
<p>The protocol and statistical analysis plan can be obtained by contacting the corresponding author. The study team will retain the exclusive use of data until publication of major outputs has been completed. Guy’s and St Thomas’ NHS Foundation Trust and King’s College London are co-sponsors of this research project and have shared data controller responsibilities.</p></section></section><section id="s4"><h2 class="pmc_sec_title">Discussion</h2>
<p>This trial aims to provide a comprehensive mixed-methods assessment of the feasibility of JAK inhibitor therapy in PPP. Progression criteria (‘feasible’/’intermediate’/’non-feasible’) have been outlined to determine whether it is appropriate to progress to a definitive trial. Qualitative findings will be used to inform ‘intermediate’ results in any domain.</p>
<p>This trial employs several innovative approaches. The first is the use of placebo data from the APRICOT as historic controls. This trial will generate an indication of effect size, informing subsequent power calculations for future adequately powered clinical trials. Alongside efficiency savings, this design also mitigates the ethical concerns of giving a placebo treatment to trial participants, given the known marked burden of disease associated with PPP. The use of historic controls is established in oncology and certain rare disease trial contexts. There is one reported study in dermatology using historic controls in a comparison of surgical techniques, and none investigating drug therapies.<a href="#R44" class="usa-link" aria-describedby="R44"><sup>44</sup></a> This is, therefore, an exciting opportunity to pilot this trial design in an inflammatory dermatological setting, while also maximising the efficiency of this feasibility study.</p>
<p>The QRI approach represents a further opportunity for innovation. Embedding this iterative methodology within the feasibility trial will allow for an agile, adaptive approach, with the trial design and participant recruitment strategies finessed over the course of the trial. These strategies can then be incorporated into future research efforts to aid the efficiency and success of a definitive trial.</p>
<p>A limitation of this study is the planned single-arm, open-label trial design. Participants may be more willing to participate in a single-arm study than a RCT. To mitigate this, this topic will be explored in the integrated qualitative study, with participants asked whether they would consider participating in a definitive trial with a placebo arm in the future. Further limitations are the short duration (8 weeks) of the trial, and the lack of a planned open-label extension. These limitations were explored as part of the PPI panel discussion during the planning and design of the study and were felt to be acceptable provided they were adequately explained to potential participants prior to enrolment. This is also a single-centre study, based in a tertiary dermatology centre, and so the findings may not be generalisable to a multi-centre RCT involving secondary care centres. Barriers to implementation in other care settings will be explored in the qualitative interviews with healthcare professionals.</p></section><section id="s5"><h2 class="pmc_sec_title">Supplementary material</h2>
<section class="sm xbox font-sm" id="SP1"><div class="caption p"><span>online supplemental file 1</span></div>
<div class="media p" id="d67e1630">
<div class="caption">
<a href="/articles/instance/12374624/bin/bmjopen-15-8-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">bmjopen-15-8-s001.docx</a><sup> (189.9KB, docx) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.1136/bmjopen-2025-106361</div>
</div></section><section class="sm xbox font-sm" id="SP2"><div class="caption p"><span>online supplemental file 2</span></div>
<div class="media p" id="d67e1635">
<div class="caption">
<a href="/articles/instance/12374624/bin/bmjopen-15-8-s002.docx" data-ga-action="click_feat_suppl" class="usa-link">bmjopen-15-8-s002.docx</a><sup> (44.6KB, docx) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.1136/bmjopen-2025-106361</div>
</div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>Data from the APRICOT (NIHR reference: 13/50/17; REC reference: 16/LO/0436; ISRCTN number: ISCRTN13127147) will be used as historic placebo control data in this study.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn16"><p><strong>Funding:</strong> NIHR303264, supporting DG as an NIHR Doctoral Training Fellow. NIHR302258, supporting SM’s NIHR Advanced Fellowship. CS is supported by an NIHR Senior Investigator Award. This research is funded/supported by the King’s Health Partners Centre for Translational Medicine. The views expressed are those of the author(s) and not necessarily those of King’s Health Partners.</p></div>
<div class="fn p" id="fn17"><p>Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<a href="https://doi.org/10.1136/bmjopen-2025-106361" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1136/bmjopen-2025-106361</a>).</p></div>
<div class="fn p" id="fn18"><p><strong>Provenance and peer review:</strong> Not commissioned; peer reviewed for ethical and funding approval prior to submission.</p></div>
<div class="fn p" id="fn19"><p><strong>Patient consent for publication:</strong> Not applicable.</p></div>
<div class="fn p" id="fn20"><p><strong>Patient and public involvement:</strong> Patients and/or the public were involved in the design, conduct, reporting or dissemination plans of this research. Refer to the Methods section for further details.</p></div>
</div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="R1">
<span class="label">1.</span><cite>Ramcharran D, Strober B, Gordon K, et al.  The Epidemiology of Palmoplantar Pustulosis: An Analysis of Multiple Health Insurance Claims and Electronic Health Records Databases. Adv Ther. 2023;40:5090–101. doi: 10.1007/s12325-023-02669-w.</cite> [<a href="https://doi.org/10.1007/s12325-023-02669-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10567878/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37737889/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Adv%20Ther&amp;title=The%20Epidemiology%20of%20Palmoplantar%20Pustulosis:%20An%20Analysis%20of%20Multiple%20Health%20Insurance%20Claims%20and%20Electronic%20Health%20Records%20Databases&amp;author=D%20Ramcharran&amp;author=B%20Strober&amp;author=K%20Gordon&amp;volume=40&amp;publication_year=2023&amp;pages=5090-101&amp;pmid=37737889&amp;doi=10.1007/s12325-023-02669-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R2">
<span class="label">2.</span><cite>Benzian-Olsson N, Dand N, Chaloner C, et al.  Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. JAMA Dermatol. 2020;156:1216–22. doi: 10.1001/jamadermatol.2020.3275.</cite> [<a href="https://doi.org/10.1001/jamadermatol.2020.3275" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7495329/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32936291/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Dermatol&amp;title=Association%20of%20Clinical%20and%20Demographic%20Factors%20With%20the%20Severity%20of%20Palmoplantar%20Pustulosis&amp;author=N%20Benzian-Olsson&amp;author=N%20Dand&amp;author=C%20Chaloner&amp;volume=156&amp;publication_year=2020&amp;pages=1216-22&amp;pmid=32936291&amp;doi=10.1001/jamadermatol.2020.3275&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R3">
<span class="label">3.</span><cite>Obeid G, Do G, Kirby L, et al.  Interventions for chronic palmoplantar pustulosis: abridged Cochrane systematic review and GRADE assessments. Br J Dermatol. 2021;184:1023–32. doi: 10.1111/bjd.19560.</cite> [<a href="https://doi.org/10.1111/bjd.19560" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32961599/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Dermatol&amp;title=Interventions%20for%20chronic%20palmoplantar%20pustulosis:%20abridged%20Cochrane%20systematic%20review%20and%20GRADE%20assessments&amp;author=G%20Obeid&amp;author=G%20Do&amp;author=L%20Kirby&amp;volume=184&amp;publication_year=2021&amp;pages=1023-32&amp;pmid=32961599&amp;doi=10.1111/bjd.19560&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R4">
<span class="label">4.</span><cite>McCluskey D, Benzian-Olsson N, Mahil SK, et al.  Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis. Journal of Allergy and Clinical Immunology. 2022;150:882–93. doi: 10.1016/j.jaci.2022.04.027.</cite> [<a href="https://doi.org/10.1016/j.jaci.2022.04.027" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35568077/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Journal%20of%20Allergy%20and%20Clinical%20Immunology&amp;title=Single-cell%20analysis%20implicates%20TH17-to-TH2%20cell%20plasticity%20in%20the%20pathogenesis%20of%20palmoplantar%20pustulosis&amp;author=D%20McCluskey&amp;author=N%20Benzian-Olsson&amp;author=SK%20Mahil&amp;volume=150&amp;publication_year=2022&amp;pages=882-93&amp;pmid=35568077&amp;doi=10.1016/j.jaci.2022.04.027&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R5">
<span class="label">5.</span><cite>Virtanen A, Spinelli FR, Telliez JB, et al.  JAK inhibitor selectivity: new opportunities, better drugs? Nat Rev Rheumatol. 2024;20:649–65. doi: 10.1038/s41584-024-01153-1.</cite> [<a href="https://doi.org/10.1038/s41584-024-01153-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39251770/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Rheumatol&amp;title=JAK%20inhibitor%20selectivity:%20new%20opportunities,%20better%20drugs?&amp;author=A%20Virtanen&amp;author=FR%20Spinelli&amp;author=JB%20Telliez&amp;volume=20&amp;publication_year=2024&amp;pages=649-65&amp;pmid=39251770&amp;doi=10.1038/s41584-024-01153-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R6">
<span class="label">6.</span><cite>Sood S, Abduelmula A, Maliyar K, et al.  Use of Janus Kinase Inhibitor Treatment for Palmoplantar Pustulosis: An Evidence-Based Review. J Cutan Med Surg. 2024;28:86–7. doi: 10.1177/12034754231211342.</cite> [<a href="https://doi.org/10.1177/12034754231211342" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37937880/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cutan%20Med%20Surg&amp;title=Use%20of%20Janus%20Kinase%20Inhibitor%20Treatment%20for%20Palmoplantar%20Pustulosis:%20An%20Evidence-Based%20Review&amp;author=S%20Sood&amp;author=A%20Abduelmula&amp;author=K%20Maliyar&amp;volume=28&amp;publication_year=2024&amp;pages=86-7&amp;pmid=37937880&amp;doi=10.1177/12034754231211342&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R7">
<span class="label">7.</span><cite>Ytterberg SR, Bhatt DL, Mikuls TR, et al.  Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;27:316–26. doi: 10.1056/NEJMoa2109927.</cite> [<a href="https://doi.org/10.1056/NEJMoa2109927" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35081280/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Cardiovascular%20and%20Cancer%20Risk%20with%20Tofacitinib%20in%20Rheumatoid%20Arthritis&amp;author=SR%20Ytterberg&amp;author=DL%20Bhatt&amp;author=TR%20Mikuls&amp;volume=27&amp;publication_year=2022&amp;pages=316-26&amp;pmid=35081280&amp;doi=10.1056/NEJMoa2109927&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R8">
<span class="label">8.</span><cite>Russell MD, Stovin C, Alveyn E, et al.  JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications. Ann Rheum Dis. 2023;82:1059–67. doi: 10.1136/ard-2023-224049.</cite> [<a href="https://doi.org/10.1136/ard-2023-224049" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10359573/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37247942/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Rheum%20Dis&amp;title=JAK%20inhibitors%20and%20the%20risk%20of%20malignancy:%20a%20meta-analysis%20across%20disease%20indications&amp;author=MD%20Russell&amp;author=C%20Stovin&amp;author=E%20Alveyn&amp;volume=82&amp;publication_year=2023&amp;pages=1059-67&amp;pmid=37247942&amp;doi=10.1136/ard-2023-224049&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R9">
<span class="label">9.</span><cite>Medicines and Healthcare Prodcuts Regulatory Agency. Drug Safety Update. 2021;15:1.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Drug%20Safety%20Update&amp;title=Medicines%20and%20Healthcare%20Prodcuts%20Regulatory%20Agency&amp;volume=15&amp;publication_year=2021&amp;pages=1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R10">
<span class="label">10.</span><cite>Gleeson D, Corbett M, Choy SP, et al.  Prevalence of comorbidity amongst people with palmoplantar pustulosis: A systematic review and meta‐analysis. Acad Dermatol Venereol. 2025 doi: 10.1111/jdv.20766.</cite> [<a href="https://doi.org/10.1111/jdv.20766" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40452648/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Acad%20Dermatol%20Venereol&amp;title=Prevalence%20of%20comorbidity%20amongst%20people%20with%20palmoplantar%20pustulosis:%20A%20systematic%20review%20and%20meta%E2%80%90analysis&amp;author=D%20Gleeson&amp;author=M%20Corbett&amp;author=SP%20Choy&amp;publication_year=2025&amp;pmid=40452648&amp;doi=10.1111/jdv.20766&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R11">
<span class="label">11.</span><cite>Jacques RM, Ahmed R, Harper J, et al.  Recruitment, consent and retention of participants in randomised controlled trials: a review of trials published in the National Institute for Health Research (NIHR) Journals Library (1997-2020) BMJ Open. 2022;12:e059230.  doi: 10.1136/bmjopen-2021-059230.</cite> [<a href="https://doi.org/10.1136/bmjopen-2021-059230" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8845327/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35165116/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ%20Open&amp;title=Recruitment,%20consent%20and%20retention%20of%20participants%20in%20randomised%20controlled%20trials:%20a%20review%20of%20trials%20published%20in%20the%20National%20Institute%20for%20Health%20Research%20(NIHR)%20Journals%20Library%20(1997-2020)&amp;author=RM%20Jacques&amp;author=R%20Ahmed&amp;author=J%20Harper&amp;volume=12&amp;publication_year=2022&amp;pages=e059230&amp;pmid=35165116&amp;doi=10.1136/bmjopen-2021-059230&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R12">
<span class="label">12.</span><cite>Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86:304–14. doi: 10.4065/mcp.2010.0575.</cite> [<a href="https://doi.org/10.4065/mcp.2010.0575" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3068890/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21389250/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mayo%20Clin%20Proc&amp;title=Medication%20adherence:%20WHO%20cares?&amp;author=MT%20Brown&amp;author=JK%20Bussell&amp;volume=86&amp;publication_year=2011&amp;pages=304-14&amp;pmid=21389250&amp;doi=10.4065/mcp.2010.0575&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R13">
<span class="label">13.</span><cite>Donovan JL, Rooshenas L, Jepson M, et al.  Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI) 
Trials
. 2016;17:283. doi: 10.1186/s13063-016-1391-4.</cite> [<a href="https://doi.org/10.1186/s13063-016-1391-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4898358/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27278130/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Trials&amp;title=Optimising%20recruitment%20and%20informed%20consent%20in%20randomised%20controlled%20trials:%20the%20development%20and%20implementation%20of%20the%20Quintet%20Recruitment%20Intervention%20(QRI)&amp;author=JL%20Donovan&amp;author=L%20Rooshenas&amp;author=M%20Jepson&amp;volume=17&amp;publication_year=2016&amp;pages=283&amp;pmid=27278130&amp;doi=10.1186/s13063-016-1391-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R14">
<span class="label">14.</span><cite>Hatswell A, Freemantle N, Baio G, et al.  Summarising salient information on historical controls: A structured assessment of validity and comparability across studies. Clin Trials. 2020;17:607–16. doi: 10.1177/1740774520944855.</cite> [<a href="https://doi.org/10.1177/1740774520944855" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7649932/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32957804/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Trials&amp;title=Summarising%20salient%20information%20on%20historical%20controls:%20A%20structured%20assessment%20of%20validity%20and%20comparability%20across%20studies&amp;author=A%20Hatswell&amp;author=N%20Freemantle&amp;author=G%20Baio&amp;volume=17&amp;publication_year=2020&amp;pages=607-16&amp;pmid=32957804&amp;doi=10.1177/1740774520944855&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R15">
<span class="label">15.</span><cite>Hall KT, Vase L, Tobias DK, et al.  Historical Controls in Randomized Clinical Trials: Opportunities and Challenges. Clin Pharmacol Ther. 2021;109:343–51. doi: 10.1002/cpt.1970.</cite> [<a href="https://doi.org/10.1002/cpt.1970" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32602555/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Ther&amp;title=Historical%20Controls%20in%20Randomized%20Clinical%20Trials:%20Opportunities%20and%20Challenges&amp;author=KT%20Hall&amp;author=L%20Vase&amp;author=DK%20Tobias&amp;volume=109&amp;publication_year=2021&amp;pages=343-51&amp;pmid=32602555&amp;doi=10.1002/cpt.1970&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R16">
<span class="label">16.</span><cite>Cro S, Cornelius VR, Pink AE, et al.  Anakinra for palmoplantar pustulosis: results from a randomized, double-blind, multicentre, two-staged, adaptive placebo-controlled trial (APRICOT) Br J Dermatol. 2021;186:245–56. doi: 10.1111/bjd.20653.</cite> [<a href="https://doi.org/10.1111/bjd.20653" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9255857/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34411292/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Dermatol&amp;title=Anakinra%20for%20palmoplantar%20pustulosis:%20results%20from%20a%20randomized,%20double-blind,%20multicentre,%20two-staged,%20adaptive%20placebo-controlled%20trial%20(APRICOT)&amp;author=S%20Cro&amp;author=VR%20Cornelius&amp;author=AE%20Pink&amp;volume=186&amp;publication_year=2021&amp;pages=245-56&amp;pmid=34411292&amp;doi=10.1111/bjd.20653&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R17">
<span class="label">17.</span><cite>Collignon O, Schritz A, Spezia R, et al.  Implementing Historical Controls in Oncology Trials. Oncologist. 2021;26:e859–62. doi: 10.1002/onco.13696.</cite> [<a href="https://doi.org/10.1002/onco.13696" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8100561/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33523511/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncologist&amp;title=Implementing%20Historical%20Controls%20in%20Oncology%20Trials&amp;author=O%20Collignon&amp;author=A%20Schritz&amp;author=R%20Spezia&amp;volume=26&amp;publication_year=2021&amp;pages=e859-62&amp;pmid=33523511&amp;doi=10.1002/onco.13696&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R18">
<span class="label">18.</span><cite>Chan A-W, Tetzlaff JM, Altman DG, et al.  SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200–7. doi: 10.7326/0003-4819-158-3-201302050-00583.</cite> [<a href="https://doi.org/10.7326/0003-4819-158-3-201302050-00583" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5114123/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23295957/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Intern%20Med&amp;title=SPIRIT%202013%20statement:%20defining%20standard%20protocol%20items%20for%20clinical%20trials&amp;author=A-W%20Chan&amp;author=JM%20Tetzlaff&amp;author=DG%20Altman&amp;volume=158&amp;publication_year=2013&amp;pages=200-7&amp;pmid=23295957&amp;doi=10.7326/0003-4819-158-3-201302050-00583&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R19">
<span class="label">19.</span><cite>Silverberg JI, Gooderham MJ, Paller AS, et al.  Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2) Am J Clin Dermatol. 2024;25:485–96. doi: 10.1007/s40257-024-00853-4.</cite> [<a href="https://doi.org/10.1007/s40257-024-00853-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11070400/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38528257/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Clin%20Dermatol&amp;title=Early%20and%20Sustained%20Improvements%20in%20Symptoms%20and%20Quality%20of%20Life%20with%20Upadacitinib%20in%20Adults%20and%20Adolescents%20with%20Moderate-to-Severe%20Atopic%20Dermatitis:%2052-Week%20Results%20from%20Two%20Phase%20III%20Randomized%20Clinical%20Trials%20(Measure%20Up%201%20and%20Measure%20Up%202)&amp;author=JI%20Silverberg&amp;author=MJ%20Gooderham&amp;author=AS%20Paller&amp;volume=25&amp;publication_year=2024&amp;pages=485-96&amp;pmid=38528257&amp;doi=10.1007/s40257-024-00853-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R20">
<span class="label">20.</span><cite>Du N, Yang J, Zhang Y, et al.  Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients. Front Med. 2024;11:1476793. doi: 10.3389/fmed.2024.1476793.</cite> [<a href="https://doi.org/10.3389/fmed.2024.1476793" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11576273/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39568752/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Med&amp;title=Successful%20treatment%20of%20refractory%20palmoplantar%20pustulosis%20by%20upadacitinib:%20report%20of%2028%20patients&amp;author=N%20Du&amp;author=J%20Yang&amp;author=Y%20Zhang&amp;volume=11&amp;publication_year=2024&amp;pages=1476793&amp;pmid=39568752&amp;doi=10.3389/fmed.2024.1476793&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R21">
<span class="label">21.</span><cite>Zheng Y, Zhang X, Wang H, et al.  Clinical efficacy and safety of upadacitinib in the treatment of palmoplantar pustulosis: A single-center retrospective study. Indian J Dermatol. 2024 doi: 10.25259/IJDVL_751_2024.</cite> [<a href="https://doi.org/10.25259/IJDVL_751_2024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39635802/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Indian%20J%20Dermatol&amp;title=Clinical%20efficacy%20and%20safety%20of%20upadacitinib%20in%20the%20treatment%20of%20palmoplantar%20pustulosis:%20A%20single-center%20retrospective%20study&amp;author=Y%20Zheng&amp;author=X%20Zhang&amp;author=H%20Wang&amp;publication_year=2024&amp;pmid=39635802&amp;doi=10.25259/IJDVL_751_2024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R22">
<span class="label">22.</span><cite>Bhushan M, Burden AD, McElhone K, et al.  Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2001;145:546–53. doi: 10.1046/j.1365-2133.2001.04411.x.</cite> [<a href="https://doi.org/10.1046/j.1365-2133.2001.04411.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11703279/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Dermatol&amp;title=Oral%20liarozole%20in%20the%20treatment%20of%20palmoplantar%20pustular%20psoriasis:%20a%20randomized,%20double-blind,%20placebo-controlled%20study&amp;author=M%20Bhushan&amp;author=AD%20Burden&amp;author=K%20McElhone&amp;volume=145&amp;publication_year=2001&amp;pages=546-53&amp;pmid=11703279&amp;doi=10.1046/j.1365-2133.2001.04411.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R23">
<span class="label">23.</span><cite>Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978;157:238–44. doi: 10.1159/000250839.</cite> [<a href="https://doi.org/10.1159/000250839" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/357213/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Dermatologica&amp;title=Severe%20psoriasis--oral%20therapy%20with%20a%20new%20retinoid&amp;author=T%20Fredriksson&amp;author=U%20Pettersson&amp;volume=157&amp;publication_year=1978&amp;pages=238-44&amp;pmid=357213&amp;doi=10.1159/000250839&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R24">
<span class="label">24.</span><cite>Lopane G, et al.  Long-term wearable tele-rehabilitation of gait for persons with Parkinson’s disease: A feasibility study. Mov Disord. 2022;37</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Mov%20Disord&amp;title=Long-term%20wearable%20tele-rehabilitation%20of%20gait%20for%20persons%20with%20Parkinson%E2%80%99s%20disease:%20A%20feasibility%20study&amp;author=G%20Lopane&amp;volume=37&amp;publication_year=2022&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R25">
<span class="label">25.</span><cite>Bauer SR, Breyer BN, Oni-Orisan A, et al.  PERSONAL: Feasibility Study Protocol for Placebo-Controlled, Randomized n-of-1 Trials of Tamsulosin for Lower Urinary Tract Symptoms. 
Front Digit Health
. 2020;2:7.  doi: 10.3389/fdgth.2020.00007.</cite> [<a href="https://doi.org/10.3389/fdgth.2020.00007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8521798/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34713020/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Digit%20Health&amp;title=PERSONAL:%20Feasibility%20Study%20Protocol%20for%20Placebo-Controlled,%20Randomized%20n-of-1%20Trials%20of%20Tamsulosin%20for%20Lower%20Urinary%20Tract%20Symptoms&amp;author=SR%20Bauer&amp;author=BN%20Breyer&amp;author=A%20Oni-Orisan&amp;volume=2&amp;publication_year=2020&amp;pages=7&amp;pmid=34713020&amp;doi=10.3389/fdgth.2020.00007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R26">
<span class="label">26.</span><cite>Carlin CS, Feldman SR, Krueger JG, et al.  A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50:859–66. doi: 10.1016/j.jaad.2003.09.014.</cite> [<a href="https://doi.org/10.1016/j.jaad.2003.09.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15153885/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Acad%20Dermatol&amp;title=A%2050%%20reduction%20in%20the%20Psoriasis%20Area%20and%20Severity%20Index%20(PASI%2050)%20is%20a%20clinically%20significant%20endpoint%20in%20the%20assessment%20of%20psoriasis&amp;author=CS%20Carlin&amp;author=SR%20Feldman&amp;author=JG%20Krueger&amp;volume=50&amp;publication_year=2004&amp;pages=859-66&amp;pmid=15153885&amp;doi=10.1016/j.jaad.2003.09.014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R27">
<span class="label">27.</span><cite>Voils CI, Gavin KL, Thorpe CT, et al.  Validating a Self-Reported Medication Nonadherence Measure in the Context of Multiple Chronic Diseases and Routes of Medication Administration Among Patients with Type 2 Diabetes. Patient Prefer Adherence. 2022;16:3119–30. doi: 10.2147/PPA.S382885.</cite> [<a href="https://doi.org/10.2147/PPA.S382885" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9677928/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36419584/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Patient%20Prefer%20Adherence&amp;title=Validating%20a%20Self-Reported%20Medication%20Nonadherence%20Measure%20in%20the%20Context%20of%20Multiple%20Chronic%20Diseases%20and%20Routes%20of%20Medication%20Administration%20Among%20Patients%20with%20Type%202%20Diabetes&amp;author=CI%20Voils&amp;author=KL%20Gavin&amp;author=CT%20Thorpe&amp;volume=16&amp;publication_year=2022&amp;pages=3119-30&amp;pmid=36419584&amp;doi=10.2147/PPA.S382885&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R28">
<span class="label">28.</span><cite>Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177–86. doi: 10.1001/jama.297.2.177.</cite> [<a href="https://doi.org/10.1001/jama.297.2.177" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17213401/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Relationship%20between%20adherence%20to%20evidence-based%20pharmacotherapy%20and%20long-term%20mortality%20after%20acute%20myocardial%20infarction&amp;author=JN%20Rasmussen&amp;author=A%20Chong&amp;author=DA%20Alter&amp;volume=297&amp;publication_year=2007&amp;pages=177-86&amp;pmid=17213401&amp;doi=10.1001/jama.297.2.177&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R29">
<span class="label">29.</span><cite>Choudhry NK, Glynn RJ, Avorn J, et al.  Untangling the relationship between medication adherence and post-myocardial infarction outcomes: medication adherence and clinical outcomes. Am Heart J. 2014;167:51–8. doi: 10.1016/j.ahj.2013.09.014.</cite> [<a href="https://doi.org/10.1016/j.ahj.2013.09.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24332142/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20Heart%20J&amp;title=Untangling%20the%20relationship%20between%20medication%20adherence%20and%20post-myocardial%20infarction%20outcomes:%20medication%20adherence%20and%20clinical%20outcomes&amp;author=NK%20Choudhry&amp;author=RJ%20Glynn&amp;author=J%20Avorn&amp;volume=167&amp;publication_year=2014&amp;pages=51-8&amp;pmid=24332142&amp;doi=10.1016/j.ahj.2013.09.014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R30">
<span class="label">30.</span><cite>Gellad WF, Thorpe CT, Steiner JF, et al.  The myths of medication adherence. Pharmacoepidemiol Drug Saf. 2017;26:1437–41. doi: 10.1002/pds.4334.</cite> [<a href="https://doi.org/10.1002/pds.4334" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28994158/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacoepidemiol%20Drug%20Saf&amp;title=The%20myths%20of%20medication%20adherence&amp;author=WF%20Gellad&amp;author=CT%20Thorpe&amp;author=JF%20Steiner&amp;volume=26&amp;publication_year=2017&amp;pages=1437-41&amp;pmid=28994158&amp;doi=10.1002/pds.4334&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R31">
<span class="label">31.</span><cite>Sarıkaya Solak S, Kara Polat A, Kilic S, et al.  Clinical characteristics, quality of life and risk factors for severity in palmoplantar pustulosis: a cross-sectional, multicentre study of 263 patients. Clin Exp Dermatol. 2022;47:63–71. doi: 10.1111/ced.14829.</cite> [<a href="https://doi.org/10.1111/ced.14829" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34236713/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Exp%20Dermatol&amp;title=Clinical%20characteristics,%20quality%20of%20life%20and%20risk%20factors%20for%20severity%20in%20palmoplantar%20pustulosis:%20a%20cross-sectional,%20multicentre%20study%20of%20263%20patients&amp;author=S%20Sar%C4%B1kaya%20Solak&amp;author=A%20Kara%20Polat&amp;author=S%20Kilic&amp;volume=47&amp;publication_year=2022&amp;pages=63-71&amp;pmid=34236713&amp;doi=10.1111/ced.14829&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R32">
<span class="label">32.</span><cite>Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib. Am J Clin Dermatol. 2020;21:783–98. doi: 10.1007/s40257-020-00548-6.</cite> [<a href="https://doi.org/10.1007/s40257-020-00548-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32776305/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Clin%20Dermatol&amp;title=Selective%20JAK1%20Inhibitors%20for%20the%20Treatment%20of%20Atopic%20Dermatitis:%20Focus%20on%20Upadacitinib%20and%20Abrocitinib&amp;author=S%20Ferreira&amp;author=E%20Guttman-Yassky&amp;author=T%20Torres&amp;volume=21&amp;publication_year=2020&amp;pages=783-98&amp;pmid=32776305&amp;doi=10.1007/s40257-020-00548-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R33">
<span class="label">33.</span><cite>Taylor PC, Fautrel B, Piette Y, et al.  Physicians’ reasons for prescribing janus kinase inhibitors (JAKi) in patients with rheumatoid arthritis (RA), and associated alignment between physicians and patients in a real-world clinical setting. Ann Rheum Dis. 2022;81:616–7. doi: 10.1136/annrheumdis-2022-eular.1646.</cite> [<a href="https://doi.org/10.1136/annrheumdis-2022-eular.1646" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Rheum%20Dis&amp;title=Physicians%E2%80%99%20reasons%20for%20prescribing%20janus%20kinase%20inhibitors%20(JAKi)%20in%20patients%20with%20rheumatoid%20arthritis%20(RA),%20and%20associated%20alignment%20between%20physicians%20and%20patients%20in%20a%20real-world%20clinical%20setting&amp;author=PC%20Taylor&amp;author=B%20Fautrel&amp;author=Y%20Piette&amp;volume=81&amp;publication_year=2022&amp;pages=616-7&amp;doi=10.1136/annrheumdis-2022-eular.1646&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R34">
<span class="label">34.</span><cite>Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34:3661–79. doi: 10.1002/sim.6607.</cite> [<a href="https://doi.org/10.1002/sim.6607" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4626409/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26238958/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Stat%20Med&amp;title=Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies&amp;author=PC%20Austin&amp;author=EA%20Stuart&amp;volume=34&amp;publication_year=2015&amp;pages=3661-79&amp;pmid=26238958&amp;doi=10.1002/sim.6607&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R35">
<span class="label">35.</span><cite>Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101. doi: 10.1191/1478088706qp063oa.</cite> [<a href="https://doi.org/10.1191/1478088706qp063oa" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Qual%20Res%20Psychol&amp;title=Using%20thematic%20analysis%20in%20psychology&amp;author=V%20Braun&amp;author=V%20Clarke&amp;volume=3&amp;publication_year=2006&amp;pages=77-101&amp;doi=10.1191/1478088706qp063oa&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R36">
<span class="label">36.</span><cite>Perski O, Short CE. Acceptability of digital health interventions: embracing the complexity. Transl Behav Med. 2021;11:1473–80. doi: 10.1093/tbm/ibab048.</cite> [<a href="https://doi.org/10.1093/tbm/ibab048" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8320880/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33963864/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transl%20Behav%20Med&amp;title=Acceptability%20of%20digital%20health%20interventions:%20embracing%20the%20complexity&amp;author=O%20Perski&amp;author=CE%20Short&amp;volume=11&amp;publication_year=2021&amp;pages=1473-80&amp;pmid=33963864&amp;doi=10.1093/tbm/ibab048&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R37">
<span class="label">37.</span><cite>Rooshenas L, Elliott D, Wade J, et al.  Conveying Equipoise during Recruitment for Clinical Trials: Qualitative Synthesis of Clinicians’ Practices across Six Randomised Controlled Trials. PLoS Med. 2016;13:e1002147.  doi: 10.1371/journal.pmed.1002147.</cite> [<a href="https://doi.org/10.1371/journal.pmed.1002147" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5068710/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27755555/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20Med&amp;title=Conveying%20Equipoise%20during%20Recruitment%20for%20Clinical%20Trials:%20Qualitative%20Synthesis%20of%20Clinicians%E2%80%99%20Practices%20across%20Six%20Randomised%20Controlled%20Trials&amp;author=L%20Rooshenas&amp;author=D%20Elliott&amp;author=J%20Wade&amp;volume=13&amp;publication_year=2016&amp;pages=e1002147&amp;pmid=27755555&amp;doi=10.1371/journal.pmed.1002147&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R38">
<span class="label">38.</span><cite>Donovan JL, Paramasivan S, de Salis I, et al.  Clear obstacles and hidden challenges: understanding recruiter perspectives in six pragmatic randomised controlled trials. Trials. 2014;15:1–12.:5.  doi: 10.1186/1745-6215-15-5.</cite> [<a href="https://doi.org/10.1186/1745-6215-15-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3892115/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24393291/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Trials&amp;title=Clear%20obstacles%20and%20hidden%20challenges:%20understanding%20recruiter%20perspectives%20in%20six%20pragmatic%20randomised%20controlled%20trials&amp;author=JL%20Donovan&amp;author=S%20Paramasivan&amp;author=I%20de%20Salis&amp;volume=15&amp;publication_year=2014&amp;pages=1-12&amp;pmid=24393291&amp;doi=10.1186/1745-6215-15-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R39">
<span class="label">39.</span><cite>Mills N, Donovan JL, Wade J, et al.  Exploring treatment preferences facilitated recruitment to randomized controlled trials. J Clin Epidemiol. 2011;64:1127–36. doi: 10.1016/j.jclinepi.2010.12.017.</cite> [<a href="https://doi.org/10.1016/j.jclinepi.2010.12.017" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3167372/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21477994/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Epidemiol&amp;title=Exploring%20treatment%20preferences%20facilitated%20recruitment%20to%20randomized%20controlled%20trials&amp;author=N%20Mills&amp;author=JL%20Donovan&amp;author=J%20Wade&amp;volume=64&amp;publication_year=2011&amp;pages=1127-36&amp;pmid=21477994&amp;doi=10.1016/j.jclinepi.2010.12.017&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R40">
<span class="label">40.</span><cite>Jepson M, Elliott D, Conefrey C, et al.  An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. J Clin Epidemiol. 2018;99:75–83. doi: 10.1016/j.jclinepi.2018.02.018.</cite> [<a href="https://doi.org/10.1016/j.jclinepi.2018.02.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6015122/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29505860/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Epidemiol&amp;title=An%20observational%20study%20showed%20that%20explaining%20randomization%20using%20gambling-related%20metaphors%20and%20computer-agency%20descriptions%20impeded%20randomized%20clinical%20trial%20recruitment&amp;author=M%20Jepson&amp;author=D%20Elliott&amp;author=C%20Conefrey&amp;volume=99&amp;publication_year=2018&amp;pages=75-83&amp;pmid=29505860&amp;doi=10.1016/j.jclinepi.2018.02.018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R41">
<span class="label">41.</span><cite>Mills N, Blazeby JM, Hamdy FC, et al.  Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients’ treatment preferences. Trials. 2014;15:323.  doi: 10.1186/1745-6215-15-323.</cite> [<a href="https://doi.org/10.1186/1745-6215-15-323" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4138384/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25115160/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Trials&amp;title=Training%20recruiters%20to%20randomized%20trials%20to%20facilitate%20recruitment%20and%20informed%20consent%20by%20exploring%20patients%E2%80%99%20treatment%20preferences&amp;author=N%20Mills&amp;author=JM%20Blazeby&amp;author=FC%20Hamdy&amp;volume=15&amp;publication_year=2014&amp;pages=323&amp;pmid=25115160&amp;doi=10.1186/1745-6215-15-323&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="R42">
<span class="label">42.</span><cite>Alliance JL. Psoriasis priority setting partnership top 10. 2018. <a href="https://www.jla.nihr.ac.uk/priority-setting-partnerships/psoriasis/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.jla.nihr.ac.uk/priority-setting-partnerships/psoriasis/</a> Available.</cite>
</li>
<li id="R43">
<span class="label">43.</span><cite>Medical Research Council Clinical Trials Series  MRC guidelines for management of global health trials involving clinical or public health interventions. 2022</cite>
</li>
<li id="R44">
<span class="label">44.</span><cite>Cohen AJ, Talasila S, Lazarevic B, et al.  Combination cryotherapy and intralesional corticosteroid versus steroid monotherapy in the treatment of keloids. J Cosmet Dermatol. 2023;22:932–6. doi: 10.1111/jocd.15520.</cite> [<a href="https://doi.org/10.1111/jocd.15520" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36409313/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cosmet%20Dermatol&amp;title=Combination%20cryotherapy%20and%20intralesional%20corticosteroid%20versus%20steroid%20monotherapy%20in%20the%20treatment%20of%20keloids&amp;author=AJ%20Cohen&amp;author=S%20Talasila&amp;author=B%20Lazarevic&amp;volume=22&amp;publication_year=2023&amp;pages=932-6&amp;pmid=36409313&amp;doi=10.1111/jocd.15520&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><article class="sub-article" id="sub-article1"><section class="pmc-layout__citation font-secondary font-xs"><div>BMJ Open. 2025 Aug 21.</div></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Review Process File</h1></hgroup><ul class="d-buttons inline-list"><li><button class="d-button" aria-controls="clp_a.c" aria-expanded="false">Copyright and License information</button></li></ul>
<div class="d-panels font-secondary-light"><div id="clp_a.c" class="d-panel p" style="display: none"><div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div></div></div>
<div></div>
</div></section><section class="body sub-article-body"><hr class="headless">
<figure class="fig xbox font-sm" id="d67e2761"><div class="media p"><div class="caption">
<a href="/articles/instance/12374624/bin/bmjopen-2025-106361.reviewer_comments.pdf" data-ga-action="click_feat_suppl" class="usa-link">bmjopen-2025-106361.reviewer_comments.pdf</a><sup> (78KB, pdf) </sup>
</div></div>
<div class="p text-right font-secondary"><a href="figure/d67e2761/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section></article><article class="sub-article" id="_ad93_"><section class="pmc-layout__citation font-secondary font-xs"><div></div></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Associated Data</h1></hgroup><ul class="d-buttons inline-list"></ul>
<div class="d-panels font-secondary-light"></div>
<div></div>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
</div></section><section class="body sub-article-body"><section id="_adsm93_" lang="en" class="supplementary-materials"><h2 class="pmc_sec_title">Supplementary Materials</h2>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>online supplemental file 1</span></div>
<div class="media p">
<div class="caption">
<a href="/articles/instance/12374624/bin/bmjopen-15-8-s001.docx" data-ga-action="click_feat_suppl" class="usa-link">bmjopen-15-8-s001.docx</a><sup> (189.9KB, docx) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.1136/bmjopen-2025-106361</div>
</div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="caption p"><span>online supplemental file 2</span></div>
<div class="media p">
<div class="caption">
<a href="/articles/instance/12374624/bin/bmjopen-15-8-s002.docx" data-ga-action="click_feat_suppl" class="usa-link">bmjopen-15-8-s002.docx</a><sup> (44.6KB, docx) </sup>
</div>
<div class="object-id font-xs text-base-dark">DOI: 10.1136/bmjopen-2025-106361</div>
</div></section></section></section></article><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from BMJ Open are provided here courtesy of <strong>BMJ Publishing Group</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1136/bmjopen-2025-106361"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/bmjopen-15-8.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (939.3 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12374624/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12374624/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12374624%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12374624/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12374624/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12374624/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40840981/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12374624/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40840981/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12374624/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12374624/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="Nz5dikxeblEvae1apHx2fxHMX6Y4vXvEc0jvTKF2F4olNKfoSSv2YAYGr2zRGdWt">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
